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Abstract
CD4+ T cells are critical regulators of adaptive immune responses. CD4+ T cell activation is initiated and
shaped by CD4+ T cell receptor (TCR) recognition of cognate peptide/major histocompatibility complex II
(MHCII) complexes on the surface of antigen presenting cells (APCs). MHCII presentation of antigenic
peptides has historically been viewed as a property restricted to a subset of immune cells deemed
“professional” APCs – dendritic cells, macrophages, and B cells – that constitutively express MHCII.
However, recently it has been demonstrated that various other immune and non-immune cell types can
express MHCII, and that these “atypical” APCs make essential contributions to the regulation of CD4+ T
cell responses in the periphery. In the distal lung, type II alveolar cells (AT2s), epithelial cells whose main
functions are to produce surfactant and facilitate lung regeneration, have also been reported to express
MHCII at homeostasis. However, the contribution of AT2 MHCII to lung adaptive immune responses, and
the factors driving its expression, are unknown. Here we explore both the regulation and function of
MHCII on AT2s. First, we demonstrate that AT2s constitutively express high levels of MHCII in a manner
that does not require induction by inflammatory stimuli, making them unique among all other previously
studied non-immune cells. Using mouse models, we also demonstrate that AT2 MHCII participates in lung
immune responses in vivo. At homeostasis, aged mice lacking AT2 MHCII have lower frequencies of lung
T cells with an antigen-experienced phenotype. Furthermore, following respiratory viral infection, the
absence of AT2 MHCII results in increased morbidity and mortality. In both of these settings, the
contribution of AT2 MHCII is moderate. Consistent with this more modest impact, we find that AT2s
demonstrate a globally limited capacity to present antigen via MHCII. We propose that the combination of
high MHCII expression with restrained MHCII antigen presentation enables AT2s to contribute to lung
immune responses in a more measured fashion, preventing excessive inflammation that would be
damaging to the delicate gas-exchange lung parenchyma.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Immunology

First Advisor
Laurence C. Eisenlohr

Keywords
Antigen presentation, MHC class II, Type II alveolar cell

Subject Categories
Allergy and Immunology | Immunology and Infectious Disease | Medical Immunology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3990

THE REGULATION AND FUNCTION OF MAJOR HISTOCOMPATIBILITY
COMPLEX II ON LUNG TYPE II ALVEOLAR CELLS

Sushila Ann Toulmin
A DISSERTATION
in
Immunology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2020

Supervisor of Dissertation
_________________________
Laurence C. Eisenlohr, V.M.D., Ph.D.
Professor of Pathology and Laboratory Medicine

Graduate Group Chairperson
_________________________
David Michael Allman, Ph.D.
Professor of Pathology and Laboratory Medicine

Dissertation Committee
Scott E. Hensley, Ph.D., Associate Professor of Microbiology
Carolina B. Lopez, Ph.D., Professor of Molecular Microbiology
Sunny Shin, Ph.D., Associate Professor of Microbiology
G. Scott Worthen, M.D., Professor of Pediatrics

ACKNOWLEDGMENTS
The work in this dissertation was only made possible by the contributions of
countless others, who provided me with invaluable personal support and scientific
guidance over the years.
First and foremost, I would like to thank my family, whose support from
across the country and world has always been a constant grounding force. In
particular, I would like to express my most sincere and heartfelt gratitude to my
parents; without their lifelong unconditional love and support, this thesis would never
have been possible. I am especially grateful to my mum, Pragna, for all of her pride
in me and my work, and for being an incredible example of strength and resilience. I
am also extremely thankful to my sister Asha, for always being there for me so
completely in the way only a sister can, during my lowest lows and my highest highs.
Thank you also to my sister Alice, for always reminding me to be good to myself in
the midst of all of the hard work. And a special thank you to Tómas Andersen, for his
love and support throughout medical and graduate school, and for always believing
in me and encouraging me to keep going when I didn’t think I could.
I am also deeply grateful for the support and friendship of my colleagues over
the years. To my 2014 entering MSTP/IGG classmates Ruth, Emma, and Samir,
thank you for genuinely understanding all of the ins and outs of this journey. In
particular, to Ruth, thank you for our countless early morning science/life/exercise
sessions that helped me keep perspective throughout. To the fantastic members of
Eisenlohr laboratory, you are truly a special group; thank you for making lab such a
warm place and for being a second family to me. In particular, I am deeply indebted
to Chaitali Bhadiadra, who single handedly made all of the in vivo studies possible,
ii

and whose energy and empathy fueled me at a time when I needed it most. I am
also extremely thankful for the friendship and mentorship of Mike Hogan, whose
intelligence and enthusiasm for research were an infectious and invaluable part of
my scientific training in the lab.
Innumerable people within the Penn immunology, virology, and lung biology
communities helped me to think about and gain a deeper understanding of this work.
In particular, I am grateful to Andrew Paris and Scott Worthen, for helping me get
started in the lung world, and for providing valuable insight throughout.
I am also so fortunate to have had numerous mentor figures who have
contributed greatly to my scientific development. I am grateful to my thesis
committee members for their invaluable feedback and encouragement over the last
three years. I would like to especially thank Scott Hensley, whose continued support
and mentorship since my first lab rotation at Penn has made a profound impact on
my training. I am also deeply grateful to Steve Migueles, for inspiring me to become
a physician-scientist, and for his guidance and friendship during my time at the NIH
and beyond.
Lastly, I cannot imagine having navigated this work without the incredible
mentorship of Ike Eisenlohr. To Ike, thank you for sharing your scientific philosophy
and so much of your time with me, and for your endlessly bright outlook that
invariably outshone my gloomy one. Thank you for your enthusiasm for this work,
your constant encouragement, and for calling me out when I needed it while always
having my back. You are a fantastic scientist and a truly good human being, and I
am so lucky to have learned from you.

iii

ABSTRACT
THE REGULATION AND FUNCTION OF MAJOR HISTOCOMPATIBILITY
COMPLEX II ON LUNG TYPE II ALVEOLAR CELLS

Sushila A. Toulmin
Laurence C. Eisenlohr

CD4+ T cells are critical regulators of adaptive immune responses. CD4+ T cell
activation is initiated and shaped by CD4+ T cell receptor (TCR) recognition of cognate
peptide/major histocompatibility complex II (MHCII) complexes on the surface of
antigen presenting cells (APCs). MHCII presentation of antigenic peptides has
historically been viewed as a property restricted to a subset of immune cells deemed
“professional” APCs – dendritic cells, macrophages, and B cells – that constitutively
express MHCII. However, recently it has been demonstrated that various other
immune and non-immune cell types can express MHCII, and that these “atypical”
APCs make essential contributions to the regulation of CD4+ T cell responses in the
periphery. In the distal lung, type II alveolar cells (AT2s), epithelial cells whose main
functions are to produce surfactant and facilitate lung regeneration, have also been
reported to express MHCII at homeostasis. However, the contribution of AT2 MHCII
to lung adaptive immune responses, and the factors driving its expression, are
unknown. Here we explore both the regulation and function of MHCII on AT2s. First,
we demonstrate that AT2s constitutively express high levels of MHCII in a manner that
does not require induction by inflammatory stimuli, making them unique among all
other previously studied non-immune cells. Using mouse models, we also
iv

demonstrate that AT2 MHCII participates in lung immune responses in vivo. At
homeostasis, aged mice lacking AT2 MHCII have lower frequencies of lung T cells
with an antigen-experienced phenotype. Furthermore, following respiratory viral
infection, the absence of AT2 MHCII results in increased morbidity and mortality. In
both of these settings, the contribution of AT2 MHCII is moderate. Consistent with this
more modest impact, we find that AT2s demonstrate a globally limited capacity to
present antigen via MHCII. We propose that the combination of high MHCII expression
with restrained MHCII antigen presentation enables AT2s to contribute to lung immune
responses in a more measured fashion, preventing excessive inflammation that would
be damaging to the delicate gas-exchange lung parenchyma.
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CHAPTER 1:
GENERAL INTRODUCTION
1.1 Introduction to the immune system
The mammalian immune system is composed of an extensive network of
cells, as well as intracellular, cell-surface, and secreted molecules. Exquisitely
precise coordination of all of these factors is required for the appropriate recognition
of foreign substances and the execution of robust, yet regulated, defenses against
them. Both the failure to identify harmful substances and the inappropriate
recognition of harmless or host-derived molecules as foreign can result in disease;
similarly, effector responses that are inadequate, as well as responses that are too
strong and uncontrolled, can both be damaging. The immune system must therefore
constantly maintain a fine balance and does so by integrating multiple layers of
countless cellular and molecular inputs.
Immune responses can be broadly classified into two main classes: innate
and adaptive [1]. Innate immune responses are initiated quickly, within hours of
exposure a harmful stimulus. They are classically associated with barrier sites of
continuous pathogen exposure, such as the skin, lung, or gut, and they are targeted
against broadly conserved pathogen or tissue damage associated motifs. In
contrast, adaptive immune responses are slower, developing over the course of
days, but are much more precisely targeted against the specific offending infectious
agent. Adaptive immune responses are also unique in that they generate
immunological memory, such that upon re-exposure to the same specific pathogen,
responses will be faster and more robust. During host responses to many infections,
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such as viruses, both innate and adaptive immune responses represent sequential
and integrated phases of host defense. This dissertation primarily addresses the
adaptive component of antiviral host immune responses.
By far the most well studied cell types involved in the orchestration of
adaptive immune responses are conventional immune cells, which are derived from
hematopoietic stem cells (HSCs) in the bone marrow. Out of the many different
hematopoietic immune cell types, this dissertation explores the functions of the
classical antigen-presenting cells (APCs), which include dendritic cells (DCs), B
cells, and macrophages, and their interactions with one of the main adaptive immune
cell lineages, CD4+ T cells.
The contributions of all other cell types, ie: those that are not derived from
HSCs, to adaptive immune responses are far less well understood. One notable
exception is thymic epithelial cells (TECs), nonhematopoietic cells of the thymus that
have been well studied for their critical function in T cell development. Otherwise, the
role that other “non-immune” cells of the body, such as those that compose
functional organs and tissues, may play in adaptive immune responses has
historically not been the subject of extensive investigation. In this thesis I focus on
the contribution of one particular non-immune cell type, the lung type II alveolar cell
(AT2), to antiviral adaptive immune responses in the lower respiratory tract.
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1.2 T cell responses in antiviral adaptive immunity
T cells and B cells represent the two main arms of adaptive immune effector
responses. Here, I detail the general functions of T cells, with particular attention to
the CD4+ T cell lineage.
CD4+ T “helper” (Th) cells play a central role in coordinating essentially all
adaptive immune responses. Their main effector functions are to secrete instructive
cytokines and to provide stimulatory signals to potentiate and alter the functions of
other immune cell types. CD4+ T cells can adopt a number of different helper
phenotypes that are each optimal for a distinct immune context. Major CD4+ Th
phenotypes include Th1 that predominates during viral infections, Th2 during allergic
and helminth responses,Th17 during responses to extracellular pathogens, as well
as T follicular helper (Tfh) cells that are specialized for B cell help and regulatory T
(Treg) cells that contribute to immunosuppressive responses [2]. During lung viral
infections, CD4+ T cells mainly adopt a type 1 (Th1) phenotype that enhances the
antiviral immune response. These cells secrete effector cytokines (IFN-γ, TNF-α, IL2), help B cells to produce high-affinity neutralizing antibodies, enhance CD8+ T cell
cytolysis of infected cells and memory formation, and in some cases are directly
cytolytic [3]. In these cases, a different CD4+ T cell phenotype-driven response, such
as Th2, worsens disease by enhancing immunopathology in the lung [4, 5]; thus, the
development of appropriate Th function is critical. The mechanisms governing CD4+
T cell activation and differentiation are detailed in the subsequent sections.
Unlike CD4+ T cells, CD8+ T cells do not adopt such distinct phenotypes to
the same extent, but they nonetheless also play critical roles in immune responses
via their cytolytic function. During viral infections, their main functions are to secrete
3

effector cytokines, primarily IFN-γ and TNF-α, and to eliminate infected cells directly
via the delivery of perforin and granzymes to the infected cell [6].

1.3 The T cell – APC interaction
CD4+ T cells are activated by T cell receptor (TCR) recognition of antigenic
protein-derived peptides bound to major histocompatibility complex II (MHCII)
proteins on the surface of APCs. The activation of naïve T cells, or “priming”, occurs
in secondary lymphoid organs, such as lymph nodes, and is mediated by a
professional APC, usually a DC. Aside from recognition of a particular peptide/MHCII
complex, activation of a naïve T cell is also thought to require a second
costimulatory signal. This “signal 2” is typically provided by APC-derived CD80 or
CD86 binding to CD28 on the T cell surface, and its absence results in T cell anergy
rather than activation [1, 7-9]. The functional outcome of CD4+ T cell activation is
further influenced by specific cytokine signals provided by the APC at the time of
activation [2]. Altogether, the cytokine milieu present, in combination with
costimulatory signals as well as the strength and duration of the peptide/MHCII
interaction [10, 11], dictates the activation and Th phenotype that will be adopted by
the CD4+ T cell. CD8+ T cell activation occurs in a similar manner, although the CD8+
T cell TCR recognizes specific peptide/MHCI complexes (not MHCII).
After T cell activation occurs, effector T cells proliferate, then exit the lymph
nodes and traffic to the site of injury or infection. Effector T cell activation is further
modulated in the periphery by interaction with cognate peptide/MHC expressing cells
that express a diverse array of additional costimulatory molecules, inhibitory receptor
4

ligands, and adhesion molecules, which may serve to re-expand or suppress T cells
[7, 8, 12-14]. The phenotypic function of CD4+ T cells may also be altered in tissues
by peripheral MHCII-expressing cells and changes in the cytokine environment,
although the true plasticity of Th phenotypes is not fully understood [15, 16].
As recognition of specific peptide in the context of MHCII is a critical
requirement for both CD4+ T cell priming and downstream regulation in the
periphery, a major emphasis of this work is to understand how the formation of these
peptide/MHCII complexes is regulated. This includes understanding how antigenic
peptides are generated from source proteins and delivered to MHCII molecules, as
well as how MHCII protein expression is restricted in a cell-type specific manner.

1.4 Pathways of MHCII antigen processing and presentation
There are a variety of pathways by which peptides may be generated and
loaded onto MHCII. These pathways can be broadly classified based on whether
they use extracellular or intracellular proteins as initial substrates.
MHCII presentation of peptides derived from extracellular proteins has
historically been the most well studied and characterized by far. In the “classical”
pathway of exogenous MHCII presentation, extracellular protein is first taken up by
an APC into an endocytic compartment [17]. Protein degradation then occurs in the
endosomal network, with the final peptides being generated in the late endosome
[18]. Nascent MHCII molecules are synthesized in the endoplasmic reticulum (ER)
and are composed of one a and one b chain [18]. In the ER, these MHCII
heterodimers associate with the chaperone protein invariant chain, which stabilizes
5

MHCII and helps it traffic to the late endosomal compartment [19-21]. In the late
endosome, invariant chain is degraded by cathepsin proteases into the class IIassociated invariant chain peptide (CLIP), which remains in the MHCII peptide
binding groove [22-26]. Another chaperone protein, H2M, then facilitates the removal
of CLIP, which then allows the binding of antigenic peptides [27-30]. Peptide/MHCII
complexes then traffic to the cell surface [17, 18].
Deviations from the classical pathway of MHCII presentation that still rely on
the uptake of extracellular antigen include different locations of peptide generation
and loading. One alteration involves the generation of peptides that bind to MHCII
molecules in the early endosome rather than the late endosome; this scenario also
differs in that the source of MHCII is primarily recycling MHCII from the cell surface,
rather than de novo synthesized MHCII, and that peptide loading can be either H2M
dependent or independent [31-34]. This is most likely predominant for epitopes that
would be otherwise fully degraded by the harsher pH and proteolytic environments of
the late endosome or for scenarios in which MHCII biosynthesis is halted. Another
alternative to the classical pathway is the loading of pre-formed extracellular
peptides. While the loading of synthetic peptides is commonly used as an in vitro
laboratory experimental tool, there is also evidence that extracellular processing and
loading occurs in vivo [35-38]. Whether these peptides directly displace other MHCIIbound peptides on the cell surface or require internalization for loading is still unclear
[39, 40].
Apart from the MHCII presentation of extracellularly acquired antigen, MHCII
molecules also efficiently present peptides derived from intracellularly produced
proteins. Although this property was demonstrated more than 30 years ago [41-45],
6

and has been demonstrated to be the predominant mechanism of epitope generation
in certain settings, such as influenza virus infections [46], comparatively little
attention has been paid to understanding the mechanisms by which endogenous
MHCII processing and presentation occur. Studies that have explored these
mechanisms demonstrate that a highly complex system of intracellular machinery is
involved, which spans multiple subcellular compartments and can include factors
such as cytosolic proteases, lysosomal enzymes, and the macroautophagy pathway
[46-51]; however, the precise processing mediators required differ depending on the
particular epitope produced. Because of this complexity, and the relative lack of
mechanistic work in this area, the exact cellular factors required for the MHCII
presentation of intracellular antigens are far less well characterized compared to
classical MHCII presentation of exogenous antigen and seem to represent more of a
“network” rather than one linear pathway. Nonetheless, one prerequisite for all
endogenous processing and presentation is that, by definition, proteins must be
synthesized de novo inside an APC. Thus, these protein substrates include host
proteins as well as intracellularly produced pathogen-derived proteins, such as viral
proteins synthesized within directly infected cells.
The wide variety of methods by which peptides may be generated and loaded
onto MHCII diversifies the potential repertoire of MHCII-restricted peptides that can
be presented by APCs. Furthermore, as there is no one strict set of machinery
required for the generation of all epitopes, this suggests that MHCII antigen
processing can be performed by a variety of different MHCII-expressing cell types,
with each APC type using its own unique cohort of cellular mediators. This
maximizes the likelihood that an MHCII-expressing cell type will be capable of
7

presenting antigen, but also suggests that there is substantial variability in antigen
presentation capacity among candidate APCs both in aggregate and on an epitopespecific basis. Such complexity also suggests that there are numerous points where
epitope generation and presentation may be regulated.

1.5 The regulation of MHCII expression
Transcription of MHCII is driven by the class II transactivator (CIITA), a nonDNA-binding co-activator. CIITA initiates transcription by binding to a ubiquitously
expressed protein complex (composed of RFX, CREB/ATF, and NF-Y), which then
binds to a conserved promoter-proximal enhancer SXY element upstream of the
MHCII a and b chain gene loci [52]. CIITA then recruits chromatin remodeling
complexes and the transcriptional machinery to facilitate gene expression, and may
facilitate long-range promoter interactions to enhance expression as well [52, 53].
As the SXY module is also present upstream of the MHCII associated genes
encoding the invariant chain, H2M, and the H2M-antagonist H2O, expression of
these genes is coregulated along with MHCII by CIITA [54]. Although CHIP-seq,
ATAC-seq, and DNAse hypersensitivity studies have demonstrated that CIITA is
also present at hundreds of other locations within the genome that are not typically
associated with MHCII, it is unclear to what extent this translates into true
transcriptional regulation and whether these targets require CIITA binding for
transcription [55-57].
Unlike most other genes, which rely on combinatorial transcription factor
binding to modulate transcription, the transcription of MHCII is essentially exclusively
8

controlled by CIITA. Thus, MHCII expression is regulated by the mechanisms that
regulate the transcription and expression of CIITA.
Transcription of CIITA begins at three distinct promoter sites within the CIITA
locus: pI, pIII, and pIV. Transcriptional initiation occurs at each promoter in response
to different cell-type and context-specific stimuli. By convention, homeostatic
recruitment of pI occurs in conventional DCs and macrophages, and pIII in B cells
and plasmacytoid DCs, while CIITA pIV is recruited in nonhematopoietic cell types in
response to the inflammatory cytokine IFNg [58]. Thus, it is thought that DCs,
macrophages, and B cells express MHCII constitutively, while nonhematopoietic
cells only do so in the setting of inflammation. However, there are an increasing
number of notable exceptions to this paradigm, as discussed in 1.7. The three
transcripts produced from pI, pIII, and pIV each differ in their first exon, and the
resulting proteins at their N termini, but all are thought to function similarly in
inducing expression of MHCII and associated genes [58].
Apart from the CIITA-induced transcription and expression of MHCII, cells
may also acquire MHCII protein from extrinsic sources. There are three main
mechanisms by which has been described to occur [59]. The first is by trogocytosis,
a process in which direct cell-to-cell contact facilities the transfer of membranes
rapidly between two cells [60, 61]; in this case the transferred membrane would
contain MHCII proteins. The second is by exosome-mediated transfer, whereby an
MHCII+ cell releases small membrane vesicles [62] carrying MHCII molecules, that
are then taken up by a recipient cell [63]. The third is via tunneling nanotubes, or
long membrane protrusions that enable the transfer of cytoplasmic material as well
as cell surface molecules between cells [64, 65].
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1.6 The professional APCs and the requirements of an APC
Historically, MHCII antigen presentation has been studied as a property
restricted to the group of cells termed “professional APCs”: B cells, macrophages,
and DCs. A defining feature of this group is that, as discussed above, these cell
types express MHCII at homeostasis by virtue of constitutive CIITA expression.
Another key hallmark is that they are each highly specialized for the processing and
presentation of antigen via MHCII, with particularly well-developed mechanisms of
antigen uptake, degradation, and MHCII loading [17]. For example, circulating DCs
exhibit robust macropinocytosis, which allows them to continuously sample and take
up a wide variety of potential antigens that could be presented via MHCII [17, 66].
DCs are also highly phagocytic, as are macrophages [17, 67]. Furthermore, B cells
exhibit extremely efficient endocytic uptake of proteins for which their B cell
receptors (BCR) are specific [68-70]. The subcellular compartments of all three cell
types are also uniquely tailored to MHCII antigen presentation; they contain an
assortment of critical antigen processing and presentation enzymes and
chaperones, and they are dynamically regulated in response to environmental cues
to either promote or inhibit the presentation of antigens via MHCII [17, 69, 71-74].
However, as discussed above, besides the professional APCs, a variety of
other cell types express MHCII in response to IFNg induction of CIITA pIV (and in
other scenarios [to be discussed in 1.7]). Therefore, a better understanding of
whether these “non-professional” MHCII-expressing cells can also act as APCs, and
the possible contributions they might make as a result, is warranted. To this end, I
begin by summarizing the key “required” features of an APC that would endow a
non-professional MHCII+ cell with MHCII antigen presentation capacity.
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(1) The first requirement is antigen uptake. As discussed in 1.4, MHCII molecules
can present antigen from either intracellular or extracellular protein sources.
Thus, all cell types should be capable of this “antigen uptake” step in general to
some degree, as all cells express their own intracellular proteins. For the
presentation of a peptide from a specific protein, this would necessitate that the
cell could take up the protein of interest into the endocytic pathway from the
extracellular space, or that the cell produce the specific protein de novo, either a
self-protein or a pathogen protein when directly infected.
(2) After antigen uptake, appropriate proteolysis and peptide transport would be
required. Thus, the cell must express enzymes capable of protein degradation,
but also possess a proteolytic environment that is not so harsh that all epitopes
are destroyed before the possibility of loading onto MHCII [75-77]. Most cells
possess this capability to some degree, although the precise proteases and
protein processing enzymes expressed varies considerably between cell types.
As discussed in 1.4, the specific degradative enzymes required are epitope
dependent; thus, for the MHCII presentation of a specific epitope of interest, a
cell would have to express the suite of enzymes required for generation of that
particular peptide. Apart from the capacity to generate peptide fragments, a cell
would also need to have appropriate transporters or vesicular trafficking and
maturation to allow the peptides to reach the MHCII loading compartments,
depending on where the peptide is initially generated and where it is loaded
onto MHCII.
(3) A third critical property is the appropriate stabilization and trafficking of MHCII
to the peptide loading compartment. By convention, this is accomplished by the
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chaperone protein invariant chain [19-21]. However, cells from invariant chain
deficient mice still express appreciable levels of surface MHCII, although they
are reduced relative to their wild-type counterparts (Fig 1.1). Thus, while
expression of invariant chain likely enhances presentation by a cell, it is not
absolutely required for MHCII stabilization or trafficking, or for presentation [78,
79].
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Figure 1.1: Invariant chain deficient mouse DCs express MHCII. MHCII protein expression by
CD103+ DCs from naïve C57Bl/6 (B6) wild-type (WT), invariant chain deficient (Cd74-/-), and
MHCII-/- mouse lungs measured by flow cytometry; represents n=3 mice per strain.

(4) The next step required for antigen presentation is peptide binding to MHCII. In
the classical model of MHCII presentation, this requires the peptide-loading
chaperone H2M, which unloads CLIP from the MHCII peptide-binding groove in
the late endosome, allowing for the loading of other peptides. However, H2M is
more accurately described as a peptide “editor” that exchanges lower affinity
peptides for higher affinity ones. Thus, only some peptides are favored by
and/or require the presence of H2M, such as those with (i) high affinity for
MHCII, (ii) those restricted by MHCII molecules with high affinity for CLIP, or
(iii) those loaded in the late endosome, where H2M is more abundant. Peptides
that have low affinity for MHCII, are loaded in other compartments (such as the
early endosome), or bind to MHCII molecules that have a low affinity for CLIP,
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do not require H2M for loading onto MHCII and can actually be “edited out” by
H2M when it is present. Thus, H2M is not required for the loading of all MHCIIrestricted epitopes, and the presence of H2M actually hinders the presentation
of some peptides [30, 46, 80-85].
In summary, the defining characteristics of a putative MHCII+ APC – antigen uptake,
measured proteolysis, appropriate peptide and MHCII trafficking, and peptide
loading – are quite flexible in how they can be accomplished, and thus could be
theoretically fulfilled by most MHCII+ cell types in a general sense. However, MHCII
presentation capacity likely does not operate on this yes-or-no basis but instead
represents a spectrum from inefficient (less active antigen uptake, fewer proteolytic
enzymes, no chaperone expression) to highly efficient like that of professional APCs
(robust endocytosis, full suite of processing enzymes, both H2M and invariant chain
are expressed). Furthermore, inefficient versus efficient MHCII presentation capacity
can be interpreted on a global level (few versus many epitopes presented) or in
relation to one epitope in particular (low versus high levels of specific peptide/MHCII
complex formation).
Furthermore, although not required for MHCII presentation capacity, another
important APC feature that would fine-tune the function of a putative APC is the
expression of costimulatory molecules [7]. For example, expression of the
conventional costimulatory molecules CD80 or CD86 alongside peptide/MHCII
complexes would render a cell capable of priming a cognate naïve CD4+ T cell; the
absence of CD80/CD86 would instead suggest a role for the APC inducing naïve
CD4+ T cell tolerance [8, 9]. Expression of other non-canonical costimulatory
molecules, such as ICAM-1, would allow the APC to promote the activation of
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effector CD4+ T cells, whereas expression of inhibitory receptors, such as PD-L1,
would enable the suppression of CD4+ T cell effector functions by the APC [12-14,
86]. The regulated expression of a broad array of these costimulatory molecules
would endow an APC with the capacity to interact with CD4+ T cells in a fine-tuned
manner, providing activating or inhibitory cues depending upon the immunologic
context.
Overall, it is likely that most non-professional MHCII-expressing cells exhibit
MHCII antigen presentation capacity to some degree, their efficiency depending on
how well they execute the required steps of MHCII processing and presentation
outlined above; the manner in which these APCs influence CD4+ T cell function is
further influenced by the cohort of costimulatory molecules they express. Indeed,
atypical MHCII+ cells have been shown to make substantial contributions to CD4+ T
cell responses in a variety of immune settings, as detailed in the next section.

1.7 Non-professional MHCII-expressing APCs
Both at homeostasis and during disease states, there are various MHCII+
cells aside from DCs, macrophages, and B cells. Here I provide a few examples of
such cell types, and I briefly discuss the mechanisms regulating their MHCII
expression as well as their reported antigen presentation functions.
The most extensively characterized MHCII+ non-professional cell is the
thymic epithelial cell (TEC). TECs express MHCII at homeostasis. As expected,
since they are nonhematopoietic cells, their transcription of MHCII is driven by the
pIV isoform of CIITA [87]. However, departing from the paradigm discussed in 1.5,
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their recruitment of CIITA pIV is IFNg-independent. The main function of TECs is to
mediate selection of T cells in the thymus, and they directly contribute to CD4+ T cell
development by presenting antigen via MHCII [88].
Another cell type more recently described to express MHCII are intestinal
type 3 innate lymphoid cells (ILC3). ILC3s also express MHCII at homeostasis, but
despite being HSC-derived immune cells, their expression of MHCII is driven by
CIITA pIV. Similarly to TECs, they also do not require for IFNg for pIV induction [89].
MHCII antigen presentation by ILC3s to CD4+ T cells is critical for maintaining
tolerance to the gut microbiota [89, 90].
Lymph node stromal cells (LNSC) also express MHCII at homeostasis. The
expression of LNSC MHCII results from a combination of endogenous MHCII
expression as well as the exogenous acquisition of MHCII proteins from
hematopoietic cells [91-93]. In line with convention, LNSC intracellular production of
MHCII is driven by CIITA pIV and requires IFNg [91]. MHCII antigen presentation by
LNSCs to CD4+ T cells in secondary lymphoid organs contributes to the
maintenance of peripheral tolerance and Treg induction [91-94].
Although they are not professional APCs, TECs, ILC3s, and LNSCs are all
cells with primary functions in the immune system. However, several other ostensibly
“non-immune” cell types also express MHCII at homeostasis. Although the precise
CIITA regulatory mechanisms have not been explored for most of these cells, at the
time of writing, all of the cell types whose regulation has been studied have been
found to require IFNg; thus, their homeostastic MHCII expression is driven by the low
levels of IFNg present at steady-state. For example, intestinal epithelial cells (IEC)
[95], which have been demonstrated to contribute to graft-versus-host disease and
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to protect against colitis via MHCII antigen presentation to CD4+ T cells [96].
Endothelial cells (EC) are another such cell type (Figs 2.2, 2.4, 2.5), which have
been demonstrated to present antigen via MHCII and to contribute to CD4+ T cell
trafficking, effector CD4+ activation, as well as Treg induction [97-100].
The cell types discussed above are examples of some of the most well
studied non-professional MHCII-expressing cells. However, other cell types have
also been reported to express low levels of MHCII at homeostasis, and furthermore,
in the setting of inflammation, essentially all nucleated cell types (except placental
trophoblasts [101]) can be induced to produce MHCII in response to IFNg. An
exhaustive summary of the antigen presenting functions of these cell types is
beyond the scope of this dissertation, and has been reviewed thoroughly by
Kambayashi and Laufer [102] and Duraes et al [103].
Previous studies of bulk lung nonhematopoietic cells in particular have
demonstrated that they also have the capacity to act as MHCII+ APCs. For example,
in a lung transplant model, nonhematopoietic lung cells induce the formation of
Tregs in vivo [97], and flu-infected nonhematopoietic lung cells can stimulate fluspecific CD4+ T cells to produce IFNg in vitro [104]. Included in this
nonhematopoietic MHCII+ cell population are lung type II alveolar cells (AT2s). The
major focus of this dissertation is on the MHCII expression regulation and MHCII
antigen processing and presentation capacity of AT2s. AT2s have been described to
express MHCII at homeostasis in both mice [105-108] and humans [109, 110]. In the
following sections, I discuss the role of AT2s in basic respiratory homeostasis, as
well as their known functions in immune responses, in particular their interactions
with CD4+ T cells via MHCII.
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1.8 Functions of type II alveolar cells in lung physiology
The respiratory system can be functionally divided into two parts: (1) the
proximal portion responsible for conducting air, and (2) the distal portion responsible
for gas exchange. The distal lung gas exchange parenchyma is composed of alveoli,
blind-ended sacs separated by extremely thin interstitium containing pulmonary
capillaries. The alveolar structures are composed of two epithelial cell types: AT2s
and type I alveolar cells (AT1), as well as some stromal cells. AT1s are the very thin,
flat cells that facilitate gas exchange across the blood/air interface and make up
most of the surface area of the alveoli. AT2s on the other hand are much smaller,
but are more numerous, cuboidal polarized cells that also play critical roles in basic
respiratory homeostasis [111, 112].
One major function of AT2s is to produce surfactant. Surfactant is a
phospholipid-protein mixture that is secreted into the alveolar spaces, where it
reduces surface tension to prevent alveolar collapse. Defects in surfactant
production are either incompatible with life or result in severe respiratory disease.
Surfactant is composed of approximately 10% protein (including specific surfactant
proteins SP-A, SP-B, SP-C, and SP-D), and ~90% lipids/phospholipids . While some
other cell types can produce select surfactant proteins, AT2s are the only cells
capable of producing all of the lipid and protein components of surfactant, and the
only cell type that synthesizes mature SP-C protein [111-113].
AT2s possess a highly specialized network of subcellular compartments that
are tailored to the synthesis, secretion, and recycling of surfactant. The surfactant
proteins and lipids are produced in the ER, with SP-C and SP-B first synthesized as
pro-proteins. SP-A and SP-D exit the ER via the Golgi and then are released via the
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constitutive secretory pathway. In contrast, pro-SP-C and pro-SP-B, along with
lipids, traffic from the Golgi to multi-vesicular bodies (MVB), then to a specialized
lysosome-like compartment called the lamellar body (LB). Throughout this trafficking
process, pro-SP-B and pro-SP-C are subject to a number of controlled proteolytic
cleavage events carried out by processing enzymes that include cathepsins and
other proteases. The LB contents are then released into the alveolar spaces via
regulated exocytosis. Surfactant components can also be taken up from the alveolar
spaces by AT2s via endocytosis, first into early endosomes. Components can either
traffic to the lysosome for degradation, or back to the MVB where they may be either
recycled to the LB, or at that point targeted to the lysosome [111, 114].
Another major function of AT2s is to serve as stem cell-like progenitor cells in
the distal lung. AT2s are capable of proliferation, self-renewal, and terminal
differentiation, giving rise to both AT2 and AT1 daughter cells. This process operates
at homeostasis, where cell turnover is relatively slow (on the order of weeks) [111].
Additionally, after lung injury, AT2s also contribute to the repopulation of the
damaged alveolar epithelium [112, 115], in concert with other epithelial cell types
[116].
Aside from these functions in respiratory biology and lung homeostasis, AT2s
have also been described to have a number of immune functions. I will first introduce
the immunologic environment of the lower respiratory tract in 1.9 and then discuss
the known contributions of AT2s in 1.10.
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1.9 The lower respiratory tract immune system
The proximal conducting airways are lined by mucosal tissue and thus
maintain a rich mucosal immune system that is populated by numerous immune cell
types and tertiary lymphoid structures. In contrast, the gas exchange alveolated lung
parenchyma is comprised of non-mucosal thin epithelium that represents a distinct
immunologic context [117]. As this latter portion is where AT2s reside, I limit my
discussion here to the immune environment of the alveolar portion of the lower
respiratory tract.
The alveolar spaces contain a number of immune cells at homeostasis. The
most abundant are alveolar macrophages, which reside inside the alveolar spaces
[117]. There are also two main types of conventional DCs: CD103+ DCs, which lie
closer to the epithelial layer and extend processes into the alveolar spaces, and
CD11b+ DCs that reside more squarely in the interstitium [6]. The interstitium
between alveolar spaces also contains various other myeloid cells, including
interstitial macrophages, monocyte-derived DCs, and plasmacytoid DCs, as well as
T and B cells, and mast cells, NK and innate lymphoid cells, and others [6, 117].
The extensive pulmonary vasculature embedded in the lung parenchyma also
contains a variety of immune cells, including large numbers of T cells [117]. During
inflammation there is an additional influx of cell types, depending on the type of
immune response, including neutrophils, eosinophils, additional T cells, and
inflammatory monocytes, among others [6, 117].
As one area of emphasis of this dissertation is the primary T cell response to
respiratory viral pathogens, I will also outline briefly the current understanding of the
key steps in the antiviral adaptive immune response in the lung, using the response
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to influenza virus in mice as an example. The first cells to respond to influenza virus
are epithelial cells, which are the major target of infection, as well as the highly
phagocytic alveolar macrophages surveying the alveolar spaces [6]. Activation of
innate sensors within these cells leads to the production of type I/III interferons and
other inflammatory cytokines and chemokines that have direct antiviral effects and
also serve to recruit and activate other immune cells [118]. This process, along with
direct pathogen sensing, triggers antigen uptake and maturation of DCs, which then
exit the lung to enter the draining lymph nodes where they interact with naïve T cells
by presenting viral antigens via MHCI and MHCII. Although both lung DC types can
prime naïve CD4+ and CD8+ T cells, CD103+ DCs are thought to be the main
contributors to CD8+ T cell priming, arriving in large numbers to the draining lymph
node earlier during the course of infection (days 2-4). CD11b+ DCs are thought to be
more important for cytokine and chemokine production in the lung and for the
expansion of the effector T cell pool, and they peak in the lymph nodes later during
infection (days 5-7) [6]. A subset of activated CD4+ T cells remains in the lymph node
as Tfh cells that interact with B cells in germinal centers, leading to the differentiation
of flu-specific memory B cells as well as plasma cells that produce high affinity
neutralizing antibodies [6]. Antigen-specific effector Th1 CD4+ T cells and CD8+ T
cells traffic back to the lung, where they interact with both directly infected and
antigen-bearing APCs via recognition of cognate peptide/MHC complexes. These
antigen-specific T cell/APC interactions in situ are critical for direct effector T cell
functions that facilitate viral elimination, such as direct cytolysis of infected cells by
CD8s, and by CD4s to a small extent [119], as well as for Th1 CD4+ and CD8+
production of antiviral cytokines such as TNFa and IFNg. In general, these direct
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TCR-peptide/MHC interactions in the lung tissue, along with concomitant
costimulatory or inhibitory signals and particular cytokines, serve to support and
regulate the viability, proliferation, and function of effector T cells locally [6, 120-125].
Once the virus is cleared, the responding effector T cell populations contract, and a
memory T cell pool persists both centrally and in the lung tissue. A failure to properly
regulate these T cell responses, in terms of magnitude, duration, or phenotype, can
result in lung immunopathology [126].

1.10 Type II alveolar cells in lung innate and adaptive immune responses
Aside from their roles in respiratory function and lung regeneration, AT2s
have also been described to play a number of key immune functions at homeostasis
and during infection.
AT2s contribute to constitutive immune defenses in the lung. Surfactant
proteins SP-A and SP-D produced by AT2s can act as opsonins, binding to the
surface of various pathogens and accelerating their uptake by alveolar macrophages
[127]. AT2s also secrete complement components as well as lysozyme, which help
facilitate microbial clearance [128, 129]. AT2s also contribute to immune tolerance in
the lung at homeostasis by providing negative regulatory signals to alveolar
macrophages via the CD200/CD200R and TGFb axes [6, 117, 118].
During infection, AT2s express a number of pattern recognition receptors,
such as TLRs as well as the nucleic acid sensors MDA-5 and RIG-I, which allow
them to detect pathogens and initiate further immune responses [130, 131]. AT2s
can also secrete a number of different cytokines and chemokines, such as IL-6, IL-8,
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IL-1b, GM-CSF, IL-4, IFN-g, type I/III IFNs, and others, which can serve to recruit
and promote the survival and function of inflammatory cells [111, 130, 132-136].
More than 30 years ago, it was first described that AT2s express MHCII at
homeostasis in rodents and humans [137, 138], and a number of subsequent studies
have confirmed these expression findings [105-110, 139-141]. However, there have
been relatively few studies directly addressing the contribution of AT2s to adaptive
immune responses via MHCII, and those that have been performed report somewhat
conflicting functions. Cunningham and colleagues first explored the antigen
presenting capabilities of AT2s. They found that primary human AT2s were unable to
stimulate allogeneic CD4+ T cells to proliferate in a 5 day in vitro co-culture; however,
proliferation could be induced by adding high concentrations of anti-CD28 antibody
(≥10µg/mL) to the culture [110]. Debbabi et al. subsequently demonstrated that
primary murine AT2s pre-incubated with M. tuberculosis (Mtb) sonicate could
stimulate polyclonal Mtb-experienced CD4+ T cells to produce IFNg in a 48 hour in
vitro co-culture, without the need for exogenous co-stimulation. They also
demonstrated that in the presence of Mtb protein antigen, AT2s could stimulate the
Mtb-specific CD4+ T cell hybridomas to produce IL-2 [106]. Conversely, Lo and
colleagues demonstrated that ovalbumin protein (Ova) treated AT2s failed to
stimulate Ova-specific CD4+ T cell hybridomas as well as primary Ova-specific CD4+
T cells (OT-II) to produce IL-2 or proliferate, even in the presence of synthetic Ova
peptides or when the AT2s had been pre-treated in vivo with IFNg. They further
demonstrated that OT-II cells pre-incubated with AT2s in vitro become tolerized, or
are suppressed in an antigen specific manner from subsequent DC-mediated
activation [108]. In contrast, using the same Ova system, Gereke et al. demonstrated
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that primary mouse AT2s treated with Ova protein in vitro or in vivo were capable of
stimulating proliferation of naïve OT-IIs in in vitro co-culture. They also showed that
primary AT2s expressing HA protein endogenously under the SP-C promoter
(derived from SPC-HA mice) could stimulate naïve HA-specific CD4+ T cells (derived
from TCR-HA mice) to proliferate in vitro. They further proposed that the effect of
AT2s on CD4+ T cells is context dependent, as AT2s derived from TCR-HA x SPCHA mice, which experience severe autoimmune lung disease, instead induced TCRHA T cells to become Tregs in vitro rather than to proliferate. They also suggest that
AT2s mediate these dynamic interactions with naïve CD4+ T cells in vivo as well, by
demonstrating TCR-HA proliferation in the lungs of SPC-HA CD11c-DTR mice and
of SPC-HA mice treated with the lymph node egress inhibitor, FTY720; however,
whether their experimental interventions reflect endogenous MHCII antigen
presentation by AT2s or MHCII presentation by residual CD11c+ or other nonCD11c+ hematopoietic lung-resident APCs that acquire exogenous HA from the
AT2s is unclear [107].
In summary, these prior studies exhibit substantial variation in their findings of
AT2 MHCII antigen presentation capacity and its functional influence on the CD4+ T
cell response. Furthermore, only Gereke and colleagues [107] attempted to explore
the in vivo impact of AT2 MHCII presentation, and they did so in the context of a
model system that forces high and artificial protein expression in the AT2s, and
where it is unclear whether the in vivo MHCII presentation measured was mediated
by AT2s or by other lung APCs. Importantly, no prior studies have investigated the
contribution of AT2 MHCII to host defense in vivo, nor have any explored
mechanisms regulating homeostatic AT2 MHCII expression. In this dissertation, I
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aim to shed light on these previously unexplored areas and to clarify the
discrepancies previously reported in AT2 MHCII function.

1.11 Goals for the thesis
The overarching goal of this dissertation is to better understand the function
of MHCII on AT2s. Specifically, I aim to elucidate (1) how MHCII expression by AT2s
is regulated, (2) the contribution of AT2 MHCII to lung antiviral host responses, and
(3) the MHCII antigen presentation capabilities of AT2s. A driving purpose for this
work is the need to better understand how immune responses are carefully
orchestrated in the lung parenchyma to facilitate rapid pathogen clearance while
preventing collateral immunopathology that would damage the vital gas-exchange
surface; I seek to understand if and how AT2s contribute to this regulation.
In chapter 2, I investigate the MHCII+ APC characteristics of AT2s. First, I
explore the mechanisms by which AT2s express MHCII protein as well as the
transcriptional mediators and cytokine signals required for AT2 MHCII expression. I
also assess the capacity of AT2s to mediate antigen uptake and proteolysis, as well
as their expression of conventional MHCII trafficking and peptide loading
chaperones.
In chapter 3, I investigate the function of AT2 MHCII in vivo. Using a
conditional mouse model, I selectively eliminate MHCII just on AT2s. I assess the
impact of the loss of AT2 MHCII on disease and immune dysfunction at homeostasis
as well as during lower respiratory tract viral infection.
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In chapter 4, I explore the MHCII antigen presentation capabilities of AT2s. I
assess the capacity of AT2s to process and present antigens via MHCII both in vitro
and in vivo, using viral and model protein systems to look on an aggregate and
epitope-specific basis.
In chapter 5, I discuss the implications of our findings and consider future
avenues of investigation.
In chapter 6, I detail the materials and methods used for all studies in the
preceding chapters.
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CHAPTER 2:
TYPE II ALVEOLAR CELLS CONSTITUTIVELY EXPRESS MAJOR
HISTOCOMPATIBILITY COMPLEX II INDEPENDENT OF CONVENTIONAL
INFLAMMATORY MEDIATORS

Adapted from the following manuscript:

Sushila A. Toulmin, Chaitali Bhadiadra, Andrew J. Paris, Jeremy Katzen, Maria C.
Basil, Edward E. Morrisey, G. Scott Worthen, and Laurence C. Eisenlohr.
(Manuscript submitted)
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2.1 Introduction
CD4+ T cell responses are initiated by T cell receptor (TCR) recognition of
cognate major histocompatibility complex II (MHCII)/peptide complexes on the surface
of antigen presenting cells (APCs). By convention, constitutive MHCII expression is
restricted to a few specialized types of cells, including the “professional APCs” B cells,
dendritic cells (DCs), and macrophages, as well as thymic epithelial cells (TECs) [52].
In contrast, all other cell types are thought to produce MHCII only in the setting of
inflammation, specifically in response to the cytokine interferon-g (IFNg) [58].
However, more recently, an increasing number of other cell types have been shown
to express MHCII at homeostasis, violating this expression paradigm, as discussed in
1.7. These include intestinal ILC3s [89, 90], which express MHCII independent of IFNg,
as well as several nonhematopoietic cell types, such as lymph node stromal cells [9194], vascular endothelial cells [98-100], and intestinal epithelial cells [95, 96, 142],
whose MHCII production is driven by the basal IFNg present at steady state.
Type II alveolar cells (AT2s) are an additional nonhematopoietic cell type that
have been reported to express MHCII at homeostasis in both mice [105-108] and
humans [109, 110]. As described in 1.8, AT2s are epithelial cells present in the lung
parenchyma, and their main physiologic functions are to produce surfactant and to
serve as stem-like cells in the distal lung [112, 115, 143, 144]. Their constitutive MHCII
expression suggests that they may participate in lung adaptive immune responses as
well. Previous studies of AT2 MHCII function have varied widely in their findings [106108, 110], and as such, the capacity of AT2s to act as MHCII+ APCs remains unclear.
Furthermore, no prior studies have attempted to understand the mechanisms driving
this unusual homeostatic MHCII expression by AT2s. Thus, here I report on the
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mechanisms regulating AT2 MHCII expression at homeostasis, and I begin to assess
their MHCII antigen presentation capacity by evaluating the basic APC characteristics
of AT2s.
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2.2 Results
AT2s express MHCII protein at homeostasis to uniformly high levels
To verify prior reports of homeostatic AT2 MHCII expression, we assessed
MHCII on both mouse and human AT2s by flow cytometry. Mouse AT2s were
identified as CD45-CD31-EpCAMint cells (Fig 6.1) [105], while human AT2s were
identified by expression of the cell surface marker HT2-280 (Fig 6.2) [145]. Consistent
with prior studies, we found that naïve wild-type C57Bl/6 (B6) AT2s uniformly express
MHCII (Fig 2.1a). Similarly, healthy human AT2s express the human MHCII protein
HLA-DR (Fig 2.1b).

Figure 2.1: Mouse and human AT2s express MHCII at homeostasis. a, MHCII protein
expression by AT2s from naïve C57Bl/6 (B6) wild-type (WT) and MHCII-/- mice measured by flow
cytometry; represents n>10 mice per strain total from >5 independent experiments. b, MHCII
(HLA-DR) protein expression by AT2s and distal lung cells from a healthy human donor measured
by flow cytometry; represents n=1 donor, and gate was drawn based on fluorescence minus one
(FMO) controls.

We next compared MHCII levels on AT2s to other well studied MHCIIexpressing lung cells in naïve mice. AT2s express MHCII at a magnitude similar to
that of lung professional APCs, dendritic cells (DCs) and B cells, and higher than
alveolar macrophages (Fig 2.2a). Besides AT2s, vascular endothelial cells (ECs) are
another nonhematopoietic cell type in the lung that express MHCII at homeostasis
[97]. Compared to ECs, AT2 MHCII expression is higher and more homogeneous (Fig
2.2b).
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Figure 2.2: AT2s express high levels of MHCII similar to professional APCs. a,b, MHCII
protein expression by AT2s, CD103+ dendritic cells (CD103+ DC), B cells, alveolar macrophages
(Alv mac), and endothelial cells (EC), from naïve B6 WT mouse lungs measured by flow cytometry;
represents n>10 mice per strain total from >5 independent experiments.

MHCII protein may be synthesized intracellularly or extrinsically acquired [59]
from conventional APCs. We examined the source of AT2 MHCII by qPCR and by
creating CD45.1 MHCII+/+ (B6CD45.1) and CD45.2 MHCII-/- B6 (MHCII-/-) bone marrow
chimeric mice. AT2s express transcript for both the a and b chains of the MHCII allele
in B6 mice, I-Ab (Fig 2.3a), and AT2s retained MHCII protein expression to high levels
in MHCII-/- à B6CD45.1 mice (Fig 2.3b). Thus, AT2s synthesize their own MHCII and do
not depend on acquisition of MHCII protein from hematopoietic APCs.

Figure 2.3: AT2s synthesize their own MHCII transcript and protein. a, I-Ab a (H2-Aa) and b
(H2-Ab1) chain transcript abundance relative to housekeeping gene Hprt1, in AT2s and lung
dendritic cells (DC) sorted from naïve B6 WT mice, and a B6 fibroblast cell line (B6 Fib), measured
by quantitative RT-PCR; n=3 mice for AT2s, n=2 mice for DCs, bars represent mean plus standard
error of the mean (SEM), 1 representative experiment shown of 2 similar independent
experiments. b, MHCII protein expression by AT2s in MHCII-/- and CD45.1 B6 (B6CD45.1) bone
marrow chimeric mice, measured 8 weeks post-transplantation with transfers as indicated;
histograms represent n=2-4 mice per group in 1 experiment.
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In sum, AT2s represent a unique population of nonhematopoietic lung cells
that produce MHCII protein at homeostasis uniformly to high levels, similar to that of
professional APCs.

AT2 MHCII expression is regulated in an unconventional, IFNg-independent manner
The class II transactivator (CIITA) is the master transcription factor that drives
MHCII expression [58]. To determine whether AT2 MHCII expression is dependent on
CIITA, we assessed MHCII in the lungs of Ciita-/- mice. Lack of CIITA results in the
complete loss of MHCII expression on AT2s, as well as lung DCs and ECs (Fig 2.4).
As discussed in 1.5, transcription of CIITA begins at three different promoter sites (pI,
pIII, and pIV) depending on cell and context specific stimuli. Recruitment of pI occurs
in DCs and macrophages, pIII in B cells and plasmacytoid DCs, and pIV in ILC3s and
nonhematopoietic cells [58, 89]. To assess whether AT2 MHCII is dependent on pIV,
we evaluated mice lacking just the pIV region within the CIITA locus [146]. AT2s from
Ciita pIV-/- mice fail to express MHCII, as do ECs, while DCs retain MHCII expression
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as expected (Fig 2.4).

Figure 2.4: AT2 MHCII expression is driven by CIITA pIV. MHCII protein expression by AT2s,
CD103+ DCs, ECs from naïve B6 WT, MHCII-/-, Ciita-/-, and Ciita pIV-/- mouse lungs, measured by
flow cytometry. For each strain, MHCII expression is displayed as a percentage reflecting the
average median fluorescence intensity (MFI) of MHCII on each cell type relative to the average
MHCII MFI on the same cell type in WT mice; n=2-4 mice per strain total from 1-2 independent
experiments pooled. Data are shown as mean plus SEM.
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The recruitment of pIV in all nonhematopoietic cells (except for thymic epithelial
cells (TECs)) is thought to require induction by the cytokine IFNg [58]. We evaluated
MHCII in mice deficient in IFNg, IFNgR, and the associated downstream pIV-binding
transcription factor, STAT1. AT2s retain MHCII expression in Ifng-/-, Ifngr1-/-, and
Stat1-/- mice in a manner similar to DCs and in contrast to ECs, whose MHCII
expression is abrogated in the absence of IFNg signaling (Fig 2.5). AT2s, like DCs,
exhibit a small reduction in MHCII expression in Stat1-/- mice, indicating that IFNg
signaling may upregulate MHCII expression in AT2s, but it is not required for steady
state expression.
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Figure 2.5: AT2 MHCII expression does not require canonical IFNg inflammation. MHCII
protein expression by AT2s, CD103+ DCs, ECs from naïve B6 WT, MHCII-/-, Ifng-/-, Ifngr1-/-, and
Stat1-/- mouse lungs, measured by flow cytometry. For each strain, MHCII expression is displayed
as a percentage reflecting the average median fluorescence intensity (MFI) of MHCII on each cell
type relative to the average MHCII MFI on the same cell type in WT mice; n=2-4 mice per strain
total from 1-2 independent experiments pooled. Data are shown as mean plus SEM.

Besides IFNg, no other cytokine has been shown to be sufficient to induce
MHCII expression in nonhematopoietic cells. However, given the IFNg-independent
expression of MHCII by AT2s, we also examined the requirement of a broad array of
conventional innate and adaptive immune mediators, by assessing Ifnar1-/-, Ifnar1-/- x
Ifngr1-/-, Myd88-/-, Stat6-/-, and germ-free mice. AT2s express MHCII at wild-type levels
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in all cases (Fig 2.6), indicating that they also do not require a wide spectrum of other,
non-IFNg inflammatory signals for MHCII expression, including type I IFNs, TLR
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Stat6-/-
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50
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ligands, IL-1, IL-18, IL-33, Th2 cytokines, and the microbiota.

Figure 2.6: AT2s express MHCII independent of a variety of broad innate and adaptive
inflammatory mediators. MHCII protein expression by AT2s, from naïve B6 WT, MHCII-/- Stat6/, Ifnar1-/-, Ifnar1-/-Ifngr1-/-, Myd88-/-, and germ-free mice, measured by ex vivo flow cytometry
analysis and displayed as MFI of AT2s from each strain relative to WT AT2s; n=2-3 mice per strain
total from 1-2 independent experiments pooled. Data are shown as mean plus SEM.

Altogether, these data demonstrate that AT2 homeostatic MHCII expression is
CIITA pIV-dependent, but IFNg-independent. This same transcriptional configuration
has been reported for only two other cell types: TECs[87], which are present in a
primary immune organ, and ILC3s [89], which are immune cells. To our knowledge it
has never been described for a cell outside of the immune system.

AT2s possess classical APC characteristics and MHCII antigen processing and
presentation machinery
Although the spectrum of “required” machinery for MHCII antigen processing
and presentation can vary widely depending on the particular epitope generated and
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APC involved, as discussed in chapter 1, we nonetheless sought to understand to
what extent AT2s possess general characteristics that would contribute to their
capacity to act as MHCII+ APCs.
We first examined whether AT2s possess mediators of classical MHCII
presentation. By convention, this pathway begins with extracellular antigen acquisition
followed by proteolysis in the endocytic compartment [17, 18, 147]. To assess these
steps, we evaluated the capacity of AT2s to catabolize DQ-Ova, a self-quenched
conjugate of ovalbumin protein that fluoresces after receptor-mediated endocytosis
and proteolytic digestion. AT2s exhibited a temperature-dependent increase in
fluorescence when incubated with DQ-Ova, less so than DCs but similarly to B cells,
indicating that they are capable of active antigen uptake and degradation (Fig 2.7).

Figure 2.7: AT2s are capable of extracellular antigen uptake and degradation. Fluorescence
of AT2s, B cells, and DCs sorted from naïve B6 WT lungs then incubated with DQ-ovalbumin (DQova) or media at the temperatures indicated, measured by flow cytometry; histograms represent
n=2 mice total from 2 independent experiments.

Optimal MHCII presentation also requires appropriate stabilization and
trafficking of MHCII. Classically, this is facilitated by the chaperone protein invariant
chain [17, 18, 147]. We evaluated invariant chain expression by flow cytometry and,
consistent with prior reports [105, 148], found that AT2s express intracellular invariant
chain in both mice (Fig 2.8a) and humans (Fig 2.8b).
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Figure 2.8: AT2s express invariant chain protein. a, Intracellular invariant chain protein
expression by AT2s, lung CD103+ DCs, and splenic B cells from B6 WT or invariant chain deficient
(Cd74-/-) mice measured ex vivo by flow cytometry; histograms represent n=3-9 mice per strain
from 3 independent experiments. b, Intracellular invariant protein expression by AT2s and distal
lung cells from a healthy human donor measured by flow cytometry; represents n=1 donor, and
gate was drawn based on fluorescence minus one (FMO) controls.

Classical MHCII processing also depends on the protein H2M, which facilitates
removal of the invariant chain peptide remnant CLIP from the MHCII peptide-binding
groove in the late endosome [17, 18, 147]. We evaluated H2M expression by qPCR
and flow cytometry. In mice, H2M is a heterodimeric protein composed of one a chain
pairing with one of two b chains, b1 or b2 [30]; H2Mab1 and H2Mab2 are thought to
function similarly [149, 150]. AT2s expressed detectable levels of transcripts encoding
the a and b chains of H2M (Fig 2.9a), using b primers that capture both b1 and b2.
However, by flow cytometry AT2s did not express H2Mab2 protein (Fig 2.9b). Thus,
the predominant form of H2M in naïve mouse AT2s is H2Mab1, consistent with
publicly availably RNA-seq data (Fig 2.10) deposited on the LungMAP Consortium
(U01HL122642). We also evaluated H2M function by flow cytometric detection of the
CLIP/MHCII complex CLIP/I-Ab in B6 mice. If H2M is functionally present, then the
35

number of CLIP/I-Ab complexes will be low, as CLIP peptide will be edited out. AT2s
from wild-type mice have low expression of CLIP/I-Ab complexes, similar to
hematopoietic MHCII+ lung cells, and in contrast to both cell types from H2M-deficient
mice that have high levels of CLIP/I-Ab (Fig 2.9c). We also assessed the expression
of the human H2M-equivalent, HLA-DM, in human AT2s, by flow cytometry. As in
mice, healthy human AT2s expressed HLA-DM (Fig 2.9d).

Figure 2.9: AT2s express functional H2M protein. a, H2Ma and H2M-b chain transcript
abundance relative to housekeeping gene Hprt1, in AT2s and DCs sorted from naïve B6 WT
mouse lungs, and a B6 fibroblast cell line (B6 Fib), measured by quantitative RT-PCR; n=3 mice
for AT2s, n=2 mice for DCs, data shown are mean plus SEM, 1 representative experiment shown
of 2 similar independent experiments. b, Intracellular H2Mab2 protein expression by AT2s and
lung B cells from B6 WT or H2Ma deficient (H2-DMa-/-) mice measured ex vivo by flow cytometry
with frequency of H2Mab2+ cells shown; plots represent n>10 mice per strain total from >5
independent experiments. Gates were drawn separately for AT2s and B cells based on their H2Ma
deficient cell counterparts. c, Surface MHCII and CLIP/I-Ab H2Mab2 protein expression by AT2s
and bulk CD45+MHCII+ cells from B6 WT or H2Ma deficient mice measured ex vivo by flow
cytometry with frequency of MHCII+CLIP/I-Ab+ cells shown; plots represent n>6 mice per strain
total from >3 independent experiments. d, Intracellular HLA-DM protein expression by AT2s and
distal lung cells from a healthy human donor measured by flow cytometry; represents n=1 donor,
and gate was drawn based on fluorescence minus one (FMO) controls.
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Figure 2.10: AT2s express exclusively H2Mb1 transcripts, not H2Mb2, at homeostasis.
H2Mb1 and H2Mb2 chain transcript abundance measured by bulk RNA-seq, normalized by
RPKM, in AT2s from naïve 4 week old B6 mice. The results shown here are in whole based upon
data deposited on the LungMAP Consortium by J. Whitsett and Y. Xu. They were downloaded
from (www.lungmap.net), on Nov 18, 2018. The LungMAP consortium and the LungMAP Data
Coordinating Center (1U01HL122638) are funded by the National Heart, Lung, and Blood Institute
(NHLBI).

Besides extracellular antigens, MHCII also presents peptides derived from
intracellular proteins [35, 47, 49]. For example, in influenza (flu) virus infections in B6
mice, endogenous MHCII presentation of peptides from viral proteins synthesized
within infected cells, instead of engulfed extracellular viral material, drives the majority
of the antiviral CD4+ T cell response [46]. Endogenous MHCII presentation involves a
heterogenous network of machinery that are less well characterized compared to the
classical pathway, precluding an exhaustive study of specific mediators here.
However, one prerequisite for endogenous processing is expression of intracellular
antigen by the APC. We assessed whether AT2s produce viral proteins intracellularly
after exposure to live influenza virus and found that AT2s expressed both
hemagglutinin (HA) as well as nucleoprotein (NP) to high levels (Figs 4.2, 4.4). This
suggests that AT2s possess abundant substrate material for endogenous processing
during flu infections, and this presumably extends to other respiratory viral infections
for which they are also main targets.
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Beyond peptide/MHCII complex formation, another component of APC function
is the provision of costimulation. In general, priming of naïve T cells requires APC
expression of the proteins CD80 or CD86, while the reactivation of effector T cells is
less costimulation-dependent and may be influenced by a wider spectrum of
costimulatory molecules [7, 151]. Prior studies indicate that naïve AT2s do not express
CD80 or CD86, but that they express the noncanonical costimulatory molecule ICAM1 [106-108]. We also assessed AT2s for CD80, CD86, and ICAM-1 expression and
found that AT2s expressed ICAM-1, but not CD80 or CD86, both at homeostasis and
after influenza infection (Fig 2.11).

Figure 2.11: AT2s express noncanonical costimulatory molecule ICAM-1, but not CD80 or
CD86. a, Surface expression of CD80 (left) and CD86 (right) by AT2s from naïve mice or mice 5
days post influenza virus infection, and B6 WT BMDCs cultured in vitro. b, Surface expression of
ICAM-1 by AT2s from naïve mice or mice 5 days post influenza virus infection, and B6 WT
splenocytes from naïve mice. Histograms represent n=2 mice (naïve) or n=6 mice (flu infected) in
total across 2 experiments.

Taken together, these data indicate that AT2s possess the requisite
characteristics and intracellular machinery to endow them with MHCII antigen
presentation capacity; in combination with the expression of ICAM-1 but not
CD80/CD86, this would predict that AT2s have the ability to act as APCs, activating
effector, but not naïve, CD4+ T cells that enter the lung.
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2.3 Discussion
Here we establish that AT2 cells stand alone in a new category of MHCIIexpressing cells, as non-immune cells that nonetheless constitutively express MHCII
in an IFNg-independent manner. We also demonstrate that AT2s express
conventional MHCII-associated antigen processing machinery and APC qualities
that should equip them with the capacity to present antigen to CD4+ T cells.
We confirm prior reports of homeostatic MHCII expression by AT2s but also
provide new insight into the magnitude of AT2 MHCII expression. We demonstrate
that AT2s uniformly express high levels of MHCII, making them unusual in
comparison to other nonhematopoietic cell types that express MHCII at
homeostasis, which typically do so to lower levels; for example, lung endothelial cells
(Fig 2.2b) and lymph node stromal cells [93] exhibit low to intermediate levels and
much less homogeneous expression of MHCII. As AT2s comprise about 15% of lung
parenchymal cells [111], this makes them one of the most abundant high-MHCIIexpressing cells in the lung, even including the professional APCs.
Prior to our work, no previous studies of AT2s had investigated the
mechanisms driving their homeostatic MHCII expression. Based on the accepted
paradigm for MHCII expression in nonhematopoietic cells, we hypothesized that AT2
MHCII would be driven by CIITA pIV in response to IFNg. Intestinal epithelial cells,
which, like AT2s, are epithelial cells at a barrier site continuously exposed to antigen,
express MHCII at homeostasis driven by the low levels of basal IFNg that are
present at steady state [95]; we presumed that AT2s would follow this same pattern.
However, we demonstrated that AT2 MHCII, while dependent on CIITA pIV, is
independent of IFNg and a number of other mediators that span multiple broad arms
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of the immune system. This indicates that CIITA pIV recruitment in AT2s follows a
novel transcriptional induction mechanism that departs from the conventional model
of CIITA regulation for non-immune cells. Furthermore, it suggests that AT2 MHCII is
not driven by an inflammatory stimulus, but rather depends on other environmental
cues or is an intrinsic part of the AT2 identity. Future work will aim to identify the
general upstream signals and transcription factors that induce CIITA pIV and
subsequent MHCII in AT2s, as detailed in chapter 5. Regardless of the specific
mechanisms driving AT2 MHCII, constitutive expression to such high levels suggests
that AT2 MHCII plays an important functional role in the lung.
We demonstrated that AT2s are capable of acquiring exogenous and
endogenous antigens and that they express conventional MHCII processing and
presentation chaperones. Although there is no one set of intracellular mediators that
is required for all MHCII presentation, the fact that AT2s possess these
characteristics suggests that they have the capacity to be potent MHCII+ APCs. As
AT2s lack CD80/CD86 expression, this suggests that AT2s play a role in modulating
the function of lung-infiltrating effector CD4+ T cells and/or in tolerizing naïve CD4+ T
cells that migrate through the lungs [152], rather than mediating priming of naïve
CD4+ T cells.
We observed that AT2s express only the H2Mab1 isoform of H2M. We were
intrigued by this differential expression of H2Mab1 and H2Mab2, since by
convention they should be co-regulated under the control of CIITA. Per publicly
available RNA-seq data deposited in the Immunological Genome Project [153],
conventional APC populations also exhibit differential expression of H2Mab1 and
H2Mab2, and the preferred isoform differs depending on cell type (Fig 2.12). B cells
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appear to favor H2Mab2, DCs express both H2Mab1 and H2Mab2 to approximately
equal levels, while macrophages are more variable depending on the tissue of origin
but seem to favor H2Mab1 like AT2s. Given that both of these genes should
theoretically be driven by the same transcription factor, this discordant expression
suggests that there are cell-type specific mechanisms that further control
transcription of each H2Mb gene. The functional significance of this regulation is
unclear, as H2Mab1 and H2Mab2 have been shown to function similarly [149, 150],
although admittedly no prior studies have addressed this very extensively.
Furthermore, as the duplication of H2Mb seems to be unique to mice, it is unclear
what relevance this differential expression has to humans; humans have only one
gene for H2Mb, although it is polymorphic within the population as a whole [154,
155].
Overall, AT2s constitutively express high levels of MHCII and possess
promising MHCII+ APC characteristics. In the next chapter, we will directly examine
how this translates into the function of AT2 MHCII at homeostasis and during lung
infection.
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Figure 2.12: APCs differentially express H2Mb1 and H2Mb2. a-c, H2Mb1 and H2Mb2 chain
transcript abundance detected by bulk RNA-seq, normalized by DESeq2, of the splenic B cell
subsets (a), splenic DC subsets (b), and macrophage populations (c) indicated, in naïve 6 week
old B6 mice. Data were obtained from the Immunological Genome Project (ImmGen).
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CHAPTER 3:
TYPE II ALVEOLAR CELL MAJOR HISTOCOMPATIBILITY COMPLEX II
CONTRIBUTES MODESTLY TO LUNG T CELL HOMEOSTASIS AND
PROTECTION DURING RESPIRATORY VIRAL INFECTION

Adapted from the following manuscript:

Sushila A. Toulmin, Chaitali Bhadiadra, Andrew J. Paris, Jeremy Katzen, Maria C.
Basil, Edward E. Morrisey, G. Scott Worthen, and Laurence C. Eisenlohr.
(Manuscript submitted)
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3.1 Introduction
In chapter 2 we demonstrated that AT2s possess robust APC characteristics,
including constitutive and high MHCII expression. In this chapter, we examine how
these features may translate into their in vivo function.
In general, T cell responses are initiated and largely shaped by the priming of
naïve T cells and their subsequent proliferation in a draining lymph node. However,
effector T cells that then circulate back to the site of infection can also be further
regulated by cognate peptide/MHC-expressing cells in the tissue. For example, in
the lung during viral infections in particular, this has been demonstrated for both
CD8+ and CD4+ T cell function and proliferation [120, 122-125]. Furthermore, fine
tuning of CD4+ T cell responses, during either the priming or effector phase, also
occurs in a number of other tissues and can be mediated by a variety of
unconventional MHCII+ cells [102, 103]. For example, ILC3s have been
demonstrated to induce deletion of commensal-specific CD4+ T cells via MHCII
presentation in the intestine, which is critical to prevent gut immunopathology [89,
90]. Intestinal epithelial cells have also been shown to regulate gut CD4+ T cells
differentially depending on the disease setting; they contribute to worst graft-versushost disease pathogenesis by priming CD4+ T cells, but also regulate the Th1/Treg
balance in the gut to prevent colitis [95, 96]. Furthermore, MHCII presentation by
vascular endothelial cells has been demonstrated to modulate effector CD4+ T cell
functions and trafficking [98, 99], while lymph node stromal cell MHCII presentation
is important for the maintenance of peripheral CD4+ T cell tolerance [92, 94].
Regulation of CD4+ T cell function in the periphery by these MHCII+ APCs
primarily occurs via TCR binding to cognate peptide/MHCII complexes along with
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accompanying activating or inhibitory receptor/ligand interactions, which serves to
either amplify T cell activation or suppress T cell function. However, aside from
antigen presentation, MHCII can also serve another role in regulating effector T cell
function. MHCII is one of the major ligands for the inhibitory receptor LAG3, which is
expressed on activated T cells. LAG3 binds directly to surface MHCII and this
ligation results in suppression of T cell proliferation and effector function. MHCII
binding to LAG3 restrains both CD4+ and CD8+ T cell responses in a number of
disease settings, including viral infection, autoimmunity, and cancer [156].
Only one prior study has assessed the in vivo function of MHCII on AT2s and
how this might regulate T cell responses in the lung [107]. In this study, AT2s were
reported to be capable of activating naïve CD4+ T cells in the healthy mouse lung
and of inducing CD4+ Treg formation in the setting of lung inflammation. However,
how well this experimental system, which relied on forced expression of a model
protein to very high levels in AT2s and used responding TCR transgenic CD4+ T
cells, represents a physiologic setting is unclear. Furthermore, while AT2s expressed
the protein from which the MHCII-restricted epitope of interest was derived, it is
unclear whether they were interacting directly with CD4+ T cells via MHCII or were
simply releasing antigen that was then acquired and presented by professional
APCs. Thus, the in vivo contribution of AT2 MHCII is still largely unknown, and in
particular, its contribution to lung homeostasis and to lung host responses has never
been explored to our knowledge. Thus, here we examine the function of AT2 MHCII
in vivo both at homeostasis and in the setting of respiratory virus infection.
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3.2 Results
A mouse model allows inducible and selective loss of MHCII on AT2 cells

Figure 3.1: SPCDAb1 mice demonstrate specific deletion of MHCII on AT2s. a, MHCII
expression by AT2s from naïve SPC-Cre-ERT2+/- (SPCCre), H2-Ab1fl/fl (Ab1fl/fl), and SPC-CreERT2+/- × H2-Ab1fl/fl (SPCDAb1), lungs measured by flow cytometry; histograms represent n>50
mice per strain total from >10 independent experiments. b, Immunofluorescence detection of
MHCII, SPC, and E-Cadherin in Ab1fl/fl, SPCDAb1, and MHCII-/- lungs; scale bar depicts 20 µm and
images represent n=1-2 mice per strain. c, Percent of each cell type expressing MHCII protein for
lung AT2s, B cells, alveolar macrophages, CD103+ DCs, and spleen B cells and CD8+ DCs, from
naïve SPCCre, Ab1fl/fl, and SPCDAb1 mice, measured by ex vivo flow cytometry analysis; bars show
n=4 mice per strain from 1 experiment, representative of 2 similar independent experiments for
the Ab1fl/fl and SPCDAb1 strains (n=8 mice total per strain).

As AT2s express both MHCII and the conventional MHCII-associated APC
machinery, we predicted that AT2 MHCII presentation would contribute to immune
responses in vivo. To test this, we generated mice with an AT2-specific deletion of
MHCII by breeding mice to have both (1) a tamoxifen-inducible Cre enzyme controlled
by the AT2-specific surfactant protein C (SPC) promoter [157] and (2) LoxP sites
flanking exon 1 of the I-Ab b chain on both alleles [158] (SPC-Cre-ERT2+/- × H2-Ab1fl/fl;
aka “SPCDAb1”). Upon tamoxifen administration, SPCDAb1 mice exhibit uniform deletion
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of MHCII from AT2s (Fig 3.1), in contrast to the parental strains whose AT2s retain
MHCII: those expressing the Cre enzyme with a wild-type I-Ab locus (SPC-CreERT2+/- only; aka “SPCCre”), as well as those with homozygous floxed I-Ab alleles but
no Cre (H2-Ab1fl/fl only; aka “Ab1fl/fl”).
To ensure that the deletion of MHCII in SPCDAb1 mice was restricted to AT2s,
we compared MHCII on various other APCs in the lungs and spleens of all three
strains. Similar frequencies of lung B cells, alveolar macrophages, lung CD103+ DCs,
splenic B cells, and splenic CD8a+ DCs, expressed MHCII in all three strains,
suggesting that the Cre-mediated deletion of MHCII was AT2-specific (Fig 3.1c).
However, the overall magnitude of MHCII on certain APCs, such as B cells and
CD103+ DCs, was lower in both the SPCDAb1 and Ab1fl/fl mice compared to the SPCCre
strain (Fig 3.2); this suggests that in mice of the H2-Ab1fl/fl genetic background, the IAb targeting construct diminishes MHCII expression in some cell types, independent
of Cre expression. Based on these data, we considered the Ab1fl/fl mice the most
appropriate comparators for the SPCDAb1 mice, so these two strains were paired for
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Figure 3.2: Mice of the Ab1fl/fl background demonstrate lower expression of MHCII in some
professional APCs, independent of Cre. MFI of each cell type expressing MHCII protein for
lung AT2s, B cells, alveolar macrophages, CD103+ DCs, and spleen B cells and CD8+ DCs, from
naïve SPCCre, Ab1fl/fl, and SPCDAb1 mice, measured by ex vivo flow cytometry analysis; bars show
n=4 mice per strain from 1 experiment, representative of 2 similar independent experiments for
the Ab1fl/fl and SPCDAb1 strains (n=8 mice total per strain).
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AT2 MHCII contributes to lung T cell homeostasis in aged mice
We first assessed whether loss of MHCII on AT2s resulted in immune
dysfunction at homeostasis. To this end, we examined lung immune cells and splenic
T cells by flow cytometry in naïve 7-month-old and 14-month-old SPCDAb1 and Ab1fl/fl
mice.
At 14 months of age, the SPCDAb1 mice exhibited a number of differences from
Ab1fl/fl mice in the lung T cell compartment. While the overall numbers of lung CD4+
and CD8+ T cells were similar between the strains, significantly lower proportions of
CD4+ and CD8+ T cells were effector memory phenotype (CD44+ CD62L-), and higher
proportions were naïve (CD44- CD62L+), in SPCDAb1 mice compared to Ab1fl/fl mice
(Fig 3.3). Furthermore, significantly lower proportions of lung CD4+ and CD8+ T cells
in SPCDAb1 mice expressed the inhibitory receptor PD1, which is a marker of T cell
activation and/or exhaustion, and the proliferation marker Ki67 (Fig 3.3). As surface
MHCII is the main ligand for the T cell inhibitory receptor LAG3, which is also an
activation/exhaustion marker, we also evaluated LAG3-expressing T cells in the lungs
of both strains; we found that SPCDAb1 mice had reduced frequencies of LAG3+ CD4+,
but not CD8+, T cells (Fig 3.3). We also examined lung Tregs and found that the
frequency was significantly reduced in SPCDAb1mice compared to Ab1fl/fl mice (Fig 3.3).
Frequencies of CD69+CD11a+ CD4+ and CD69+ CD8+ T cells in the lungs were also
lower in SPCDAb1mice, although did not meet statistical significance for CD4+s,
reflecting lower proportions of tissue resident-memory (Trm) [159] and/or recently
activated T cells in SPCDAb1mice (Fig 3.3).
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Figure 3.3: 14-month-old SPCDAb1 mice demonstrate disrupted lung T cell homeostasis. ag, Ex vivo flow cytometry analysis of naïve 14 month old Ab1fl/fl and SPCDAb1 mice lung T cells.
Absolute number of lung CD4+ and CD8+ T cells (a), and frequency of lung CD4+ and CD8+ T cells
expressing CD44, CD62L (b), PD1 (c), Ki67 (d), LAG3 (e), Foxp3 (f), and CD69, CD11a (g), as
indicated; n=10-11 mice per strain from 1 experiment. Data shown are mean plus SEM, analyzed
by unpaired two-tailed Student’s t-test, Welch’s t-test, or Mann-Whitney test depending on the
distribution of the data.
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In contrast to the lungs, the spleen T cell compartments were more comparable
between 14-month-old SPCDAb1 and Ab1fl/fl mice, although they did demonstrate some
of the same, but less pronounced, trends in T cell activation and memory marker
expression (Fig 3.4).
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unpaired two-tailed Student’s t-test or Mann-Whitney test depending on the distribution of the data.

50

Furthermore, there were no differences in the frequencies and numbers of
other lung immune cells, including alveolar macrophages, neutrophils, NK cells, gdT
cells, and B cells between 14-month-old SPCDAb1 and Ab1fl/fl mice (Fig 3.5).
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In contrast to the 14-month-old mice, naïve 7-month-old SPCDAb1 and Ab1fl/fl
mice demonstrated no differences in numbers or frequencies of the same lung or
spleen T cell subsets or other immune cell populations (Figs 3.6-3.8).
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Overall, these data suggest that at homeostasis, AT2 MHCII facilitates the
development of various antigen-experienced lung CD4+ and CD8+ T cell populations,
including regulatory T cells, as well as memory T cells and those expressing markers
of activation and proliferation. The impact of AT2 MHCII on the T cell compartment is
less pronounced in the spleen, it does not appear to impact non-T cell lung immune
populations, and its contribution only becomes apparent with advanced mouse age.
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We next explored whether the loss of AT2 MHCII and its impact on lung T cells
might result in lung disease at homeostasis. To do this, we compared hematoxylin and
eosin (H&E) staining of naïve 9-month-old SPCDAb1 and Ab1fl/fl lungs. Both strains
demonstrated normal, healthy lung architecture with minimal infiltrates (Fig 3.9),
suggesting that loss of AT2 MHCII does not result in overt lung disease in these mice.

Ab1fl/fl

SPC

Ab1

Figure 3.9: 9-month-old SPCDAb1 mice demonstrate healthy lung histology with no
inflammatory infiltrates. H&E staining of naïve 9-month-old Ab1fl/fl and SPCDAb1 lungs,
representative of n=3 mice per strain. Scale bar depicts 100 µm.

Finally, we also investigated whether AT2 MHCII might play a non-immunologic
role at homeostasis. Specifically, we asked whether AT2 MHCII is required for the two
main physiologic functions of AT2s: lung regeneration and surfactant production. AT2s
sorted from SPCDAb1 and Ab1fl/fl mice formed similar numbers of lung organoids in vitro
(Fig 3.10). Furthermore, the SPCDAb1 mice did not experience any respiratory disease
at homeostasis, clinically or histologically (Fig 3.9); significant lung disease would be
expected if surfactant biosynthesis were disrupted. Together, this suggests that AT2
MHCII is not required for either of these critical functions.

55

b
No. of organoids/well

a
600

P = 0.22

Ab1fl/fl

SPC

Ab1

Ab1fl/fl
SPC

Ab1

400
200
0

Figure 3.10: Loss of AT2 MHCII does not affect regenerative capacity. a, b, Numbers (a) and
representative images (b) of lung organoid cultures formed by AT2s sorted from either or Ab1fl/fl
and SPCDAb1 mice. Data represent n=6 organoid cultures per strain, grown from AT2s originally
sorted from n=1 mouse per strain. a, Bars represent mean plus SEM, and the data were analyzed
by unpaired two-tailed Student’s t-test. b, Scale bar depicts 1000 µm.

In summary, at homeostasis AT2 MHCII contributes to the regulation of the
lung T cell compartment, promoting the development of various antigen-experienced
T cell subsets. However, its impact is relatively modest in magnitude, only becoming
apparent in older mice (14 m.o.), and it does not appear to result in overt lung disease.

AT2 MHCII contributes to protection from respiratory viral disease
We next assessed whether AT2 MHCII contributes to the outcome of lung

infection. To do this, we used two respiratory virus infection models: mouse lungadapted PR8 influenza A virus (IAV) as well as Sendai virus (SeV), a natural mouse
pathogen similar to human parainfluenza virus. To assess the impact of AT2 MHCII
on viral disease, we measured weight loss of SPCDAb1 and Ab1fl/fl mice after infection
with either IAV or SeV. SPCDAb1 and Ab1fl/fl mice demonstrated similar weight loss IAV
infection (Fig 3.11a, Table 3.1). However, after SeV infection, SPCDAb1 mice on
average experienced substantially more weight loss and delayed recovery compared
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to the Ab1fl/fl group (Fig 3.11b, Table 3.2). We also assessed the impact of AT2 MHCII
on mortality after infection with both viruses. SPCDAb1 mice experienced reduced
survival after IAV infection compared to Ab1fl/fl controls, 24% vs 50% respectively (Fig
3.11c). Similarly, after SeV infection, SPCDAb1 mice had worse survival with
approximately 2-fold higher mortality (28%) compared to the Ab1fl/fl controls (12%) (Fig
3.11d). Of note, here we display the aggregate analyses of multiple independent
experiments, between which we did observe some variability in disease outcome; in
some experiments the disease severity differences between the SPCDAb1 and Ab1fl/fl
mice were more pronounced, and in others less so (Fig 3.12).
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Figure 3.11: Loss of AT2 MHCII results in greater weight loss and reduced survival after
respiratory viral infection. a-d, Comparison of Ab1fl/fl and SPCDAb1 mice after infection with
influenza strain PR8 (IAV PR8) (a,c) and Sendai virus strain 52 (SeV 52) (b,d). a,b, Weight loss
with weights displayed relative to day of infection; n=43-53 mice per strain pooled from 6
independent experiments (a), and n=17-22 mice per strain pooled from 2 independent
experiments (b). c,d, Mortality, with curves representing proportion surviving; n=21-22 mice per
strain pooled from 2 independent experiments (c), and n=17-22 mice per strain pooled from 2
independent experiments (d). a,b, Data are mean plus SEM, analyzed by mixed-effects model
with post-hoc multiple comparisons with Sidak’s correction at each dpi. P values displayed
represent overall model effects. Full statistical test results are in Tables 3.1 and 3.2. c,d, Survival
curves were compared via Log-rank test.
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Figure 3.12: Differences in weight loss and survival between Ab1fl/fl and SPCDAb1 mice were
subject to experiment to experiment variation. a-d, Representative independent experiments
of Ab1fl/fl and SPCDAb1 mice after infection with influenza strain PR8 (IAV PR8) (a,c) and Sendai
virus strain 52 (SeV 52) (b,d). a,b, Weight loss with weights displayed relative to day of infection;
n=6-12 mice per strain (a, left), n=7-12 mice per strain (a, right), n=8-11 mice per strain (b, left),
and n=9-11 mice per strain (b, right). c,d, Mortality, with curves representing proportion surviving;
n=9-10 mice per strain (c, left), n=12 mice per strain (c, right), n=9-11 mice per strain (d, left),
and n=8-11 mice per strain (d, right). a-d, Data are mean plus SEM of mice within one experiment
only per graph.
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We next asked whether AT2 MHCII antigen presentation might contribute to
the control of viral replication, by measuring lung virus titers after infection with either
IAV or SeV. There were no significant differences in IAV titers 7 days after infection
between SPCDAb1 and Ab1fl/fl mice (Fig 3.13a). Similarly, SeV titers 4, 7, and 9 days
after infection were similar between the two strains (Fig 3.13b). As LAG3 has been
shown to restrict lung CD4+ and CD8+ T cell responses during respiratory viral
infections [160, 161], we also considered whether AT2 MHCII is required for LAG3mediated T cell suppression during infection. However, we found similar frequencies
and numbers of LAG3+ CD4+ and CD8+ T cells in the lungs of SPCDAb1 and Ab1fl/fl mice
9 days after IAV infection (Fig 3.14). Thus, MHCII on AT2s serves to reduce morbidity
and mortality in the setting of respiratory viral illness, without impacting LAG3+ T cell
expansion or lung viral burden.
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Figure 3.13: Loss of AT2 MHCII does not affect lung virus titers after respiratory viral
infection. Comparison of Ab1fl/fl and SPCDAb1 mice after infection with influenza strain PR8 (IAV
PR8) (a) and Sendai virus strain 52 (SeV 52) (b). Lung virus titers on the days post-infection (dpi)
indicated; n=7 mice per strain from 1 experiment (a), and n=5 mice per strain for days 4 and 9,
n=11-12 per strain for day 7, pooled from 2 independent experiments (b). Bars are mean plus
SEM of log10 transformed values, analyzed by unpaired two-tailed Student’s t-test (a), and twoway ANOVA (genotype effect: P=0.2197) with post-hoc multiple comparisons with Sidak’s
correction. P values displayed represent post-hoc comparisons (b).
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Figure 3.14: Loss of AT2 MHCII does not alter frequencies of LAG3+ T cells after influenza
virus infection. a,b Ex vivo flow cytometry analysis of LAG3 expression by CD4+ and CD8+ T
cells in Ab1fl/fl and SPCDAb1 mice. Frequency and number of lung LAG3+ CD4+ (a) and CD8+ (b) T
cells 9 days post IAV infection; n=6 mice per strain from 1 experiment. Data shown are mean plus
SEM, and were analyzed by unpaired two-tailed Student’s t-test.

In summary, these studies suggest that in vivo AT2 MHCII expression confers
an appreciable advantage in respiratory viral disease outcome.
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Overall model effects
Factor
P-value
Time
<0.0001
Genotype
0.1696
Genotype x Time
0.0002

Post-hoc comparison results by day
Day post-infection
P-value
5
>0.9999
6
>0.9999
7
0.9995
8
>0.9999
9
>0.9999
10
0.987
11
0.8544
12
0.738
13
0.3238
14
0.6217
15
0.5448

Table 3.1: Mixed-effects model analysis results for weight loss after IAV infection. Results
of repeated measures mixed-effects model (REML) analysis with Geisser-Greenhouse
correction factoring in both genotype and day post IAV infection as variables, with post-hoc
multiple comparisons with Sidak’s correction between the strains at each time point post
infection. P values for the overall effects as well as for each post-hoc comparison are reported,
calculated based on weights expressed as a percentage of initial weight. Data depicted in this
table are in Figure 3.11a.

Overall model effects
Factor
P-value
Time
<0.0001
Genotype
0.0037
Genotype x Time
<0.0001

Post-hoc comparison results by day
Day post-infection
P-value
2
0.5271
4
0.095
5
0.1109
6
0.5318
7
0.4242
8
0.741
9
0.4465
10
0.0429
11
0.2627
12
0.6094
13
0.4114
14
0.352
15
0.2886
16
0.4587
17
0.5085

Table 3.2: Mixed-effects model analysis results for weight loss after SeV infection. Results
of repeated measures mixed-effects model (REML) analysis with Geisser-Greenhouse
correction factoring in both genotype and day post SeV infection as variables, with post-hoc
multiple comparisons with Sidak’s correction between the strains at each time point post
infection. P values for the overall effects as well as for each post-hoc comparison are reported,
calculated based on weights expressed as a percentage of initial weight. Data depicted in this
table are in Figure 3.11b.
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3.3 Discussion
Here we demonstrate that AT2 MHCII modestly improves the outcome of
respiratory virus disease in vivo, and that it also contributes to an increase in antigenexperienced T cells at homeostasis.
Given that AT2s constitutively express MHCII, we were surprised to find that
mice lacking AT2 MHCII did not exhibit overt clinical disease at homeostasis in our
studies. However, we did observe that the loss of AT2 MHCII resulted in alterations in
lung T cell phenotypes in aged mice. We found that 14-month-old mice lacking AT2
MHCII had lower frequencies of lung memory CD4+ and CD8+ T cells and higher
frequencies of naïve T cells. Furthermore, in SPCDAb1 mice, fewer lung T cells
expressed markers of activation or proliferation, and fewer CD4+ T cells had
developed into Tregs, compared to Ab1fl/fl mice. All these observations are consistent
with either less T cell activation/antigen-encounter overall, or less proliferation or
survival of antigen-experienced T cells, in the lungs of SPCDAb1 mice. We did not
observe the same impact on T cell phenotypes in the spleen – differences were
smaller, if not absent – suggesting that the impact on T cells in SPCDAb1 mice is
primarily in the lung. The most likely mechanistic explanation is that, at homeostasis,
AT2 MHCII antigen presentation to CD4+ T cells enhances the local expansion and/or
survival of antigen-specific CD4+ T cells in the lungs. As CD4+ T cell help is critical for
the development of memory CD8+ T cells [162-164], this AT2 MHCII-dependent CD4+
T cell expansion would also promote lung CD8+ T cell memory formation; this is
consistent with our observations that Ab1fl/fl control mice demonstrate higher levels of
activated and memory CD8+ T cells, in addition to CD4+s, compared to SPCDAb1 mice.
Overall, our data suggest that, at homeostasis, local AT2 MHCII antigen presentation
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promotes an increase in both antigen-experienced CD4+ and CD8+ T cells in the lungs.
We did not observe the same alterations to lung T cells in 7-month-old SPCDAb1
mice, nor did we observe any histological evidence of lung disease in 9-month-old
SPCDAb1 mice. One potential reason for this is that the specific pathogen free (SPF)
homeostasis environment of our mouse colony is characterized by artificially low levels
of antigen. Thus, the putative antigens presented by AT2 MHCII at homeostasis to
lung CD4+ T cells are limited to the narrow range of inhaled environmental antigens
present under SPF conditions. The restricted nature of these homeostatic exposures
may explain why we only observed significant impacts on the lung T cell compartment
in 14-month-old, but not 7-month-old adult mice; it is likely that a longer duration of
this low level antigen exposure is needed for the differences in T cell activation to
become amplified. Along these lines, as our lung histological analyses demonstrating
the absence of lung disease in SPCDAb1 mice were performed in 9-month-old mice, it
is possible that these studies were undertaken at too young an age; if lung pathology
were assessed at an older age, for example when T cell alterations are readily
apparent, it is possible that histological disease would be present. However, it is also
possible that under SPF conditions of such restricted antigen encounter, the modest
lessening in T cell activation and memory formation we observed would not lead to
lung disease even at an advanced age. Alternatively, it is also possible that even in
more physiologic situations of abundant environmental antigen encounter, the
contribution of AT2 MHCII may still be accessory, impacting lung T cell phenotypes,
but in a manner too small to result in true lung disease at homeostasis.
Overall, our data suggest that AT2 MHCII contributes to the development of
antigen-experienced memory, activated, and regulatory T cells in the lung at
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homeostasis. While the impact we observed was statistically significant, it represented
an overall modest change in T cell subset frequencies, and it did not result in lung
disease. We further expand on the potential reasons for this and the potential role for
AT2 MHCII at homeostasis in more detail in chapter 5.
Although the effect was not dramatic and not observed in all experiments, we
nonetheless found that, on average, AT2 MHCII also confers some degree of
protection in the setting of primary respiratory virus infection, particularly for survival.
Although the mechanism underlying this effect is still under active investigation, the
most likely explanation is that it is CD4+ T cell mediated. CD4+ T cells play a number
of important roles during the primary response to respiratory virus infections that could
be affected by the loss of MHCII AT2.
CD4+ T cells have been demonstrated to be cytolytic during influenza virus
infections [119] and can facilitate complete flu and Sendai viral clearance in CD8+ T
cell-deficient mice [165, 166]. Thus, one possibility is that AT2 MHCII facilitates CD4+
T cell recognition and killing of AT2s, which are major targets of infection in vivo,
thereby leading to faster viral clearance and improved diseased outcomes. While this
potential cytolysis may indeed be lost in SPCDAb1 mice, it does not appear to be
necessary for viral clearance or to substantially change virus loads in our studies (Fig
3.13), corroborating prior work demonstrating that nonhematopoietic cell MHCII
expression is not required for clearance of influenza virus infection [167]. Thus, loss
of CD4+ T cell cytolysis of infected AT2s is an unlikely explanation for the worse
disease we observed in SPCDAb1 mice.
Another function of CD4+ T cells during primary infection is to provide help to
CD8+ T cells, which are the major drivers of viral clearance during infection. The
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similarity in virus loads between mice with and without AT2 MHCII in both infection
models (Fig 3.13) suggests that CD8+ T cell cytolytic function is not substantially
altered. Whether or not this means that CD4+ T cell help to CD8+ T cells is also
unaffected by loss of AT2 MHCII is unclear. Mice deficient in CD4+ T cells exhibit
essentially normal viral clearance in both primary influenza and Sendai virus
infections; although CD8+ T cells may exhibit poorer per-cell cytotoxicity [168], virus
clearance in only slightly delayed [166, 168-171]. Thus, it is possible that CD4+ T cell
help is suboptimal in the absence of AT2 MHCII but this may not be manifest in bulk
virus titers at the time points studied. Even if CD4+ T cell help is impaired in SPCDAb1
mice, given that CD8+ viral clearance seems to remain intact, poor CD4+ T cell help to
CD8+s is unlikely to account for the increased mortality observed in our studies.
As virus titers were not affected by the loss of AT2 MHCII, it is possible that,
instead of an inadequate antiviral response, the lack of AT2 MHCII results in increased
immunopathology, which is what then leads to worse survival. Indeed, key future
histological studies will assess whether the increased mortality that results from loss
of AT2 MHCII is associated with more severe lung damage and inflammation. One
mechanism by which a loss of MHCII could exacerbate inflammatory damage would
be via a LAG3-dependent mechanism. The T cell inhibitory receptor LAG3 contributes
to the restriction of T cell responses during Sendai and influenza virus infections [160,
161], and MHCII is its major ligand; if MHCII specifically on AT2s is a primary ligand
for these antiviral T cells in the lung, then the loss of this inhibitory checkpoint would
result in excessive T cell expansion and inflammation. However, we demonstrated
similar numbers and frequencies of LAG3+ CD4+ and CD8+ T cells in mice with and
without MHCII on AT2s during infection, suggesting that AT2 MHCII is not required to
65

regulate this population. Thus, loss of LAG3-mediated T cell suppression is unlikely to
account for the worse disease in SPCDAb1 mice.
Another mechanism by which loss of AT2 MHCII could result in
immunopathology is by altering the cytokine production characteristics of lung
infiltrating CD4+ T cells. Although CD4+ T cells are primed in the lymph nodes to
develop into a particular Th phenotype, Th1 in the case of Sendai and influenza viral
infections, their functional properties retain some degree of plasticity and can be
further modified at the site of infection in the effector phase [6, 15, 16, 120, 121]. Thus,
it is possible that AT2s help to reinforce Th1 CD4+ phenotype and facilitate the
development of a protective CD4+ T cell cytokine milieu. Future studies will assess
whether loss of AT2 MHCII results in changes to the quality of CD4+ cytokine
production, for example skewing towards the production of Th2 or Th17 cytokines that
are associated with immunopathology [4, 5, 172].
A final possibility is that AT2 MHCII helps to facilitate proper CD4+ T cell
localization during infection to specific regions within the lung experiencing high virus
loads. Thus, AT2 MHCII may not directly lead to changes in CD4+ T cell number or
function, but instead may help to distribute them to sites experiencing particularly
severe alveolar damage. Previous studies demonstrate that during lung injury, CD4+
Tregs help to facilitate lung repair by enhancing AT2 proliferation [173, 174]. Thus, it
is possible that AT2 MHCII helps to facilitate disease recovery and prevent mortality
by targeting CD4+ T cells to the areas most in need of healing. Future imaging studies
will address this localization question.
Overall, although we did observe that loss of AT2 MHCII results in worse
survival during flu and Sendai virus infections, which may occur via the potential
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mechanisms just described, the effects were modest and not always consistent. One
possible explanation for this small effect is that in situations of inadequate CD4+ T cell
function – failure to develop cytotoxic capacity, failure to provide CD8+ T cell help, low
Th1 cytokine production – other immune mechanisms can compensate to fill the void
and facilitate recovery, masking the defect. Indeed, during primary flu or Sendai virus
infections, even mice totally deficient in CD4+ T cells experience similar disease and
mortality to wild-type mice, with almost normal virus clearance kinetics [166, 168-171]
(although, importantly, these studies were done with less pathogenic strains of
influenza and Sendai virus). Thus, it is possible that looking at clinical outcomes such
as mortality and weight loss during primary respiratory virus infection will not capture
even large differences in CD4+ T cell function that result from the loss of AT2 MHCII.
Another explanation for the small benefit afforded by AT2 MHCII is that the contribution
is truly small, that AT2 MHCII does not alter the CD4+ T cell response to a significant
degree. To understand which of these explanations is more likely, a more extensive
characterization of the antiviral CD4+ T cell response and CD4+ T cell functionality and
localization in mice with and without AT2 MHCII is needed and will be a major focus
of future study. Additionally, as discussed in chapter 5, we will explore other disease
models in which CD4+ T cell dysfunction may be more impactful and phenotypically
apparent.
We observed experiment-to-experiment variability in viral infection disease
outcome, particularly weight loss; in some experiments, SPCDAb1 mice exhibited
substantially worse weight loss compared to controls, but in other experiments they
were similar (Fig 3.12). In this dissertation we have displayed the averages and
aggregated data across all of these experiments to best summarize the consequences
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of loss of AT2 MHCII that we observed, but we still do not fully understand the reason
for such variability between experiments. The most likely explanation is that there is
an additional modifying or contributing factor that exacerbates the impact of AT2
MHCII loss; when this factor is present, the additional loss of AT2 MHCII causes
SPCDAb1 mice to have more severe disease, but when it is not, absent AT2 MHCII
expression is not sufficient to induce a worse phenotype. We explored various
explanations as to what this stochastic variable could be including mouse age, sex,
starting weight, age of tamoxifen administration, time between tamoxifen
administration and infection, and time of day at which the mice were infected. None of
these parameters appeared to explain the instances in which SPCDAb1 mice
experience more or less severe disease compared to controls.

One additional

possibility we considered was the effect of humidity, as this has been shown to alter
influenza disease severity [175]; however, the humidity in the animal facilities is
carefully controlled, and we observed variability in disease outcome in some
experiments that were performed only days apart. Another potential modifier that we
considered but have not yet explored is temporal changes in the microbiome, which is
heterogeneous in the lung across time and between mice [176], and can alter their
susceptibility to respiratory viral infections [177].
Another possible reason for the experiment to experiment variability we
observed could stem from caveats in the mouse model we used for these experiments.
As shown in Fig 3.2, mice of the floxed I-Ab background, regardless of Cre expression,
demonstrate heterogeneous and, on average, lower MHCII expression by a variety of
MHCII-expressing cell types compared to mice without floxed MHCII alleles. This
floxed I-Ab background alone increases disease severity in the mice; compared to
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SPCCre mice, the Ab1fl/fl controls look overtly more hunched, ruffled, and inactive, and
also exhibit more severe weight loss and mortality, as well as somewhat slower viral
clearance, after infection (Fig 3.15), even though both have intact AT2 MHCII
expression. Based on this observation, we used Ab1fl/fl mice as controls for the
SPCDAb1 mice in our experiments since both are subject to this floxing effect; however,
this heterogeneity in APC MHCII expression afforded by the floxed I-Ab background
could have contributed the differences in disease severity we observed. A major
reason for the inter-experiment variability we experienced was that the Ab1fl/fl control
mice exhibited different disease severity from experiment to experiment, which made
the differences relative to SPCDAb1 mice bigger or smaller; it is possible that variable
MHCII expression on key APCs from the floxed I-Ab background between experiments
contributed to different disease outcomes in the Ab1fl/fl strain. It is also possible that
there are additive effects with these alterations and loss of AT2 MHCII in the SPCDAb1
mice; for example, perhaps loss of AT2 MHCII is particularly impactful on disease
outcome in the mice with especially low DC or B cell MHCII expression from the floxed
I-Ab background. Given these considerations, an important avenue of future work in
our laboratory will be to generate a new strain of floxed I-Ab mice that do not exhibit
the same global disruptions to MHCII expression, which will ideally serve as a
“cleaner” system to isolate just the impact of AT2 MHCII.
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Figure 3.15: Ab1fl/fl control mice exhibit worse weight loss and disease and delayed viral
clearance compared to SPCCre control mice after virus infection. a-d, Comparison of Ab1fl/fl
and SPCCre mice after infection with influenza strain PR8 (IAV PR8) (a) and Sendai virus strain
52 (SeV 52) (b-d). a,b, Weight loss with weights displayed relative to day of infection; n=21-27
mice per strain pooled from 3 independent experiments (a), and n=17-20 mice per strain pooled
from 2 independent experiments (b). c, Mortality, with curves representing proportion surviving;
n=17-20 mice per strain pooled from 2 independent experiments. d, Lung virus titers on the days
post-infection (dpi) indicated; n=5 mice per strain for days 4 and 9, n=5-11 per strain for day 7,
pooled from 2 independent experiments. Bars are mean plus SEM of log10 transformed values.
a,b, Data are mean plus SEM. Mortality and viral titers of SPCCre mice after IAV PR8 infection
were not studied and therefore no graphs are shown.

In summary, we observed that loss of AT2 MHCII resulted in lower proportions
of memory, activated, and regulatory phenotype lung T cells at homeostasis, although
this effect was only apparent in in aged mice and did not result in overt lung disease.
In the setting of respiratory virus infection, we found that, on average, the loss of AT2
MHCII results in modestly increased weight loss and mortality. As previously
discussed, there are a variety of potential mechanisms underlying the effects of AT2
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MHCII we observed in vivo, both in terms of how its effects could be mediated and
why its impact is relatively small. In the next chapter, I more closely examine the latter,
by more rigorously and directly assessing the capacity of AT2s to present antigen via
MHCII to CD4+ T cells.
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CHAPTER 4:
TYPE II ALVEOLAR CELLS EXHIBIT RESTRAINED MAJOR
HISTOCOMPATIBILITY COMPLEX II ANTIGEN PRESENTATION

Adapted from the following manuscript:

Sushila A. Toulmin, Chaitali Bhadiadra, Andrew J. Paris, Jeremy Katzen, Maria C.
Basil, Edward E. Morrisey, G. Scott Worthen, and Laurence C. Eisenlohr.
(Manuscript submitted)
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4.1 Introduction
In the previous chapter, we demonstrated that loss of AT2 MHCII results in
more severe disease in the setting of respiratory virus infection. Furthermore, we
observed that in the absence of AT2 MHCII at homeostasis in aged mice, higher
proportions of lung CD4+ and CD8+ T cells remain naïve to antigen encounter.
However, the impact of AT2 MHCII was relatively modest in both cases. In 3.3 and
5.6, we discuss potential explanations for these small effects, relating to caveats of
the particular homeostasis and disease models we used. However, in this chapter,
we also explore the possibility that the more restrained impact of AT2 MHCII in vivo
results from limited AT2 MHCII presentation to CD4+ T cells.
Other groups have explored AT2 MHCII antigen presentation previously, but
their reports have been conflicting [106-108, 110]. Furthermore, in these prior
studies it is difficult to discern the true MHCII antigen presentation capacity of AT2s
for several reasons, discussed at length in 4.3 with key limitations mentioned here
briefly. One major consideration is that in all previous studies, CD4+ T cell activation
is used as the main read out of AT2 MHCII presentation; however, CD4+ T cell
activation can also be influenced by factors other than MHCII presentation, primarily
by costimulation, and this was only controlled for directly in one prior study [110].
Furthermore, in no prior studies was AT2 MHCII presentation compared directly to
that of professional APCs, and in no case was the amount of available source
antigen quantified. Therefore, the relative efficiency and magnitude of AT2 MHCII
presentation is still largely unknown. Thus, here we more rigorously examine the
capacity of AT2s to present antigen via MHCII, comparing to professional APCs,
both in vitro and in vivo in multiple antigen systems.
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4.2 Results
AT2s exhibit restrained antigen presentation capacity via MHCII
Although loss of AT2 MHCII worsened respiratory virus disease, the effect was
smaller than anticipated based on the abundance of AT2s in the lung [111] and the
magnitude of AT2 MHCII expression. A potential explanation is limited MHCII antigen
processing and presentation by AT2s, which would be advantageous in constraining
the amplification of inflammatory T cell responses that could disrupt the lung gasexchange parenchyma.
To investigate the antigen presentation function of AT2s, we first evaluated the
ability of AT2s to stimulate flu peptide/MHCII complex-specific costimulationindependent T cell hybridomas (Fig 4.1a). AT2 presentation of five different epitopes
from live virus was undetectable (Fig 4.1b,c), in contrast to professional APCs that
presented all five. Poor presentation by AT2s was not due to a failure of in vitro
infection, as AT2s were infected to levels higher than comparator professional APCs
(Fig 4.2). Limited presentation was observed across multiple MHCII alleles, B6 I-Ab
(Fig 4.1b) and BALB/c I-Ed (Fig 4.1c), was not the result of protein source, as both
HA and NA-derived epitopes were similarly affected (Fig 4.1b, c), and was similar for
epitopes generated by both exogenous (HA107-119) and endogenous (NA79-93)
processing pathways [178] (Fig 4.1c). Even when pulsed with synthetic peptides,
AT2s were able to present only three out of five epitopes (HA91-107, HA302-313, NA79-93)
(Fig 4.1b,c). Thus, AT2s exhibited a global impairment in the capacity to present
MHCII-restricted epitopes in vitro.
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Figure 4.1: AT2s exhibit a globally restricted capacity to present individual influenza virus
epitopes via MHCII in vitro. a, Schematic of hybridoma presentation assay. b,c, Presentation of
MHCII-restricted flu peptides by B6 AT2s and a mixed population of CD11c+ and CD19+ lung cells
(b) or BALB/c AT2s and CD11c+ lung cells (c) sorted from naïve mice then incubated with synthetic
peptide or live virus, reflected by NFAT-LacZ-inducible T cell hybridoma activation and cleavage
of a fluorogenic b-galactosidase substrate; bars shown represent 3 technical replicates plus SEM
from 1 experiment, representative of 3 similar independent experiments for (b).
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Figure 4.2: AT2s are robustly infected with influenza virus in vitro. Surface influenza
hemagglutinin (HA) expression by B6 AT2s (top) and a mixed population of CD11c+ and CD19+
lung cells (bottom) sorted from naïve mice then incubated with no antigen (left) or live virus (right)
in vitro for 14h. These plots reflect the APCs used in the hybridoma assay in Figure 4.1b. The
frequency of HA+ cells is shown above the gates, which were drawn based on the no antigen
conditions. Two different fluorophore conjugated versions of the same anti-HA antibody were used
because the AT2 and CD11c+/CD19+ populations were already labeled with different fluorophores
(APC and FITC, respectively) from the cell sorting process.

Assays of AT2 function in vitro may be suboptimal due to reduced viability after
cell sorting and the gradual de-differentiation of AT2s in standard tissue culture [179,
180]. Additionally, measuring presentation on an individual epitope basis may
underestimate the presentation of all possible MHCII-restricted flu peptides. Thus, we
next examined AT2 in vivo flu peptide/MHCII complex formation, by co-culturing in
vivo-infected AT2s from wild-type or MHCII-/- B6 mice taken 4 days post influenza
infection with polyclonal splenic CD4+ or CD8+ T cells taken 9 days post-infection, in
the presence of soluble anti-CD28 (Fig 4.3a). MHCII presentation was detected via T
cell IFNg production captured by ELISpot. AT2s from flu-infected mice were capable
of stimulating both CD4+ and CD8+ T cells to produce IFNg (Fig 4.3b). Stimulation of
CD4+ T cells, but not CD8+ T cells, was abrogated when MHCII-/- flu-infected AT2s
were used as APCs, confirming that stimulation of CD4+ T cells by AT2s was MHCIIdependent. However, consistent with our in vitro studies, AT2 presentation to CD4+ T
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cells was markedly less efficient than professional APCs, in this case CD103+ CD11c+
cells taken from the same lungs; despite being 9 times more infected, AT2s (99%
infected, Fig 4.4) stimulated less than half the IFNg production than the comparator
APCs (11% infected, Fig 4.4).
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Figure 4.3: In vivo-infected AT2s exhibit poor presentation of influenza virus epitopes to
polyclonal CD4+ T cells via MHCII. a, Schematic of primary T cell ELISpot presentation assay.
b, Presentation of MHCII-restricted flu peptides by lung AT2s and CD103+ CD11c+ APCs sorted
from naïve or flu-infected WT or MHCII-/- B6 mouse lungs 4 dpi, measured as the production of
IFN-g by responding flu-experienced splenic CD4+ and CD8+ T cells (as indicated); “APC %flu+”
numbers describe the proportion of each APC type that was flu-infected (shown in Fig 4.4), and
bars shown represent 1-3 technical replicates plus SEM from 1 experiment, representative of 2-3
similar independent experiments.
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Figure 4.4: AT2s are robustly infected with influenza virus in vivo. Intracellular influenza
nucleoprotein (NP) expression by B6 AT2s (top) and CD103+CD11c+ lung cells (bottom) sorted
from naïve or flu-infected WT or MHCII-/- B6 mouse lungs 4 dpi and incubated with CD4+ and CD8+
T cells in vitro for 14h (as indicated). These plots reflect the antigen presenting cells used in the
ELISpot presentation assay illustrated in Figure 4.3b. The frequency of NP+ cells is shown above
the gates, which were drawn based on the naïve conditions.

We considered that the high degree of AT2 infection in our assays might impair
their capacity to process and present antigen. To address this, we measured MHCII
antigen presentation using a non-infectious model system, by staining lungs directly
ex vivo with the peptide/MHCII complex-specific “YAe” antibody [181] (Fig 4.5a). YAe
detects Ea52-68/I-Ab complexes, which form in [BALB/c x B6] F1 mice as they are
composed of a peptide from I-Ed (BALB/c-derived) presented by I-Ab (B6-derived). In
naïve F1 mice, AT2s had low yet detectable YAe staining above the background levels
of B6 AT2s (Fig 4.5b,c). However, YAe staining of F1 AT2s was significantly lower
than that of F1 lung B cells (Fig 4.5b,c). This could not be explained by differences in
expression of the source proteins, I-Ab and I-Ed, which are similarly expressed by AT2s
and B cells at homeostasis, if not slightly higher in AT2s (Fig 4.6a,b). These results
indicate that AT2s are capable of forming Ea52-68/I-Ab complexes at steady state, but
they do so far less efficiently than do B cells.
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Figure 4.5: AT2 MHCII presentation capacity is enhanced in the setting of inflammation but
remains limited. a, Schematic of YAe presentation assay. b,c, Ea52-68/I-Ab complex formation by
AT2s and B cells, detected by ex vivo YAe antibody staining of lungs from WT B6 or F1 [BALB/c
x B6] mice treated with PBS or IFNg. b, Plots represent n=4-6 mice per group total from 2
independent experiments. c, Bars represent mean plus SEM and depict n=2-3 mice per group
from 1 experiment, representative of 2 similar independent experiments (total n=4-6). Data were
analyzed by three-way ANOVA with multiple comparisons with Sidak’s correction. P values
displayed represent post-hoc comparisons of interest.

To better approximate the setting of viral infection, we also treated mice with IFNg
and then measured Ea52-68/I-Ab complex formation. AT2 YAe staining was significantly
increased in F1 mice after treatment with IFNg, but was again lower than B cells in the
same mice (Fig 4.5b,c). To assess the contributors to increased MHCII presentation
in AT2s, we evaluated changes in expression of I-Ab, I-Ed, and H2M, all of which are
required for Ea52-68/I-Ab complex formation [80]. Both I-Ab and I-Ed increased in AT2s
after IFNg administration (Fig 4.6a,b). IFNg also induced some AT2s to express
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H2Mab2, which is absent at baseline (Fig 4.6c,d). Although H2Mab2+ AT2s exhibited
more YAe staining than H2Mab2- AT2s, both populations stained highly (Fig 4.6e),
suggesting that a higher magnitude of H2M contributes to enhanced Ea52-68/I-Ab
presentation, but the specific H2Mab2 isoform is not required. Thus, AT2 MHCII
presentation increases during IFNg inflammation due to the upregulation of several
MHCII presentation mediators, but it is still less efficient than that of professional
APCs.
Taken together, these data demonstrate that AT2s are capable of presenting
antigen via MHCII to CD4+ T cells, and this is enhanced in the setting of inflammation;
however, compared to professional APCs they exhibit limited antigen presentation of
MHCII-restricted epitopes derived from both viral and endogenous proteins, as well as
some extracellular peptides. This restrained presentation capacity may explain the
variability seen in prior studies of AT2 function owing to differences in the model
systems used, in particular the level of antigen provided to the AT2s, as well as the
specific epitopes studied.
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Figure 4.6: Expression of I-Ab, I-Ed, and H2M in AT2s increases after in vivo treatment with
IFN-g, but does not explain poor MHCII presentation. a,b, I-Ab (a) and I-Ed (b) expression by
AT2s and B cells, detected by ex vivo flow cytometry staining of lungs from MHCII-/- (II-/-) B6 (a),
WT B6 (b), or F1 (a,b) mice treated with PBS or IFNg (as indicated). c,d, Intracellular H2Mab2
expression by AT2s and lung B cells from F1 or H2-DMa-/- (Ma-/-) B6 mice treated with PBS or
IFNg. Frequency of H2Mab2+ cells is shown above gates (c), which were drawn separately for
AT2s and B cells based on corresponding H2-DMa-/- cells. e, YAe staining of H2Mab2+ and
H2Mab2- subpopulations of AT2s from B6 and F1 mice treated with IFNg. c, Plots represent n=46 mice per group total from 2 independent experiments. a,b,d,e, Bars represent mean plus SEM
and depict n=2-3 mice per group from 1 experiment, representative of 2 similar independent
experiments (total n=4-6) (d,e) or n=1-3 mice per group from 1 experiment (a,b). Data were
analyzed by two-way ANOVA with multiple comparisons with Tukey’s correction (a,b,d), and
unpaired two-tailed Student’s t-test (e). P values displayed represent post-hoc comparisons of
interest (a,b,d).
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4.3 Discussion
Here we demonstrate that, in contrast to professional APCs, AT2s exhibit a
program of globally restrained MHCII antigen presentation. We believe that our
findings represent the most accurate and definitive study of AT2 MHCII antigen
presenting function to date, in comparison to conflicting prior reports on this subject,
for the reasons outlined below.
In our assays, we used FACS to isolate AT2s, based on published cell surface
markers [105] that we also validated in house (Fig 6.1). Using this method, we
routinely obtained purities of >95%. Thus, our studies likely reflect the activities of
AT2s rather than contaminating cells.
When cultured on plastic dishes in vitro, AT2s lose their defining characteristics
and de-differentiate within a few days [144, 179, 180]. We took great care to avoid this
issue, by assessing AT2 presentation capacity directly ex vivo with no in vitro
maintenance required (YAe), or in in vitro co-cultures lasting no longer than
approximately 14 hours (hybridomas, ELISpot).

Furthermore, in two different

approaches (YAe, ELISpot), we measured AT2 peptide/MHCII complexes that formed
in vivo, to avoid artificial defects in AT2 MHCII presentation of in vitro-encountered
antigens that might be an artifact of the instability of AT2 function in vitro.
In assays where MHCII antigen presentation is detected by CD4+ T cell
activation, the provision of costimulation is a critical modifier; failure to see CD4+ T cell
activation by an APC thus can result either from poor MHCII presentation or from a
lack of costimulation. We avoided this confounding factor by using experimental
approaches that were independent of AT2-derived costimulation; T cell hybridomas
do not require costimulation, we provided exogenous anti-CD28 antibody to the
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ELISpot assay, and the YAe antibody is a direct readout of Ea52-68/I-Ab complexes.
Thus, in our studies we feel confident that we were able to isolate the effects of just
AT2 peptide/MHCII complex formation from the effect of costimulatory signals.
Another factor that directly impacts MHCII antigen presentation of a given
epitope is the availability of the source antigen to the APC. For example, an APC may
be highly capable of presenting a particular epitope, but if it expresses very low levels
of the source protein, then peptide/MHCII presentation will be low. In our assays, we
were able disentangle these influences by quantifying the antigen burden in our APCs
of interest; we measured levels of influenza virus infection (hybridomas, ELISpot) and
also quantified the levels of I-Ab and I-Ed (Yae) in AT2s and comparator APCs. Thus,
we are able to interpret true efficiency of MHCII antigen presentation relative to the
amount of available antigen.
Finally, MHCII antigen presentation capacity can be viewed on a global scale
and also in relation to one particular epitope. For example, based on the expression
of relevant processing mediators, an APC could exhibit poor ability to generate a wide
diversity of MHCII-restricted epitopes (poor global MHCII presentation), but could still
able to present a few specific peptide/MHCII complexes (efficient epitope-of-interest
presentation). In our studies, we measured both bulk AT2 MHCII presentation to
polyclonal CD4+ T cells, as well as the presentation of specific I-Ed and influenza
derived epitopes. Thus, we were able to capture MHCII presentation by AT2s at the
individual epitope level and on a broader scale by assessing multiple antigen systems
and polyclonal responses.
The variability in prior reports of AT2 MHCII antigen presentation capacity and
its impact on CD4+ T cell activation likely result from a combination of technical
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limitations and differences in how the studies were performed, particularly in relation
to the considerations discussed above. In previous studies of AT2 MHCII presentation,
the methods used to isolate AT2s were variable, as were the purities obtained.
Cunningham et al. used differential centrifugation combined with magnetic bead
depletion to isolate human AT2s; while they do not report the exact AT2 purity, it is
likely lower than that achieved by FACS [110]. Subsequent studies in mice also used
either magnetic beads or FACS for isolation, with purities ranging widely from 70% to
>95% [106-108]. Furthermore, most of these studies focused on in vitro AT2
processing and presentation, in which AT2s were placed in culture for extended
periods of time, from 48 hours up to 5 days, and at the assay endpoints AT2 cells were
not analyzed to assess the maintenance of AT2 phenotypic integrity. Additionally,
different types of CD4+ T cells used between these studies – T cell hybridomas,
primary naïve T cells, and primary effector T cells – likely contributes to the variation,
as these T cells differ in their requirement for costimulatory signals, and the role of
costimulation was not directly isolated or examined, except for in one study [110].
Finally, different model systems employed by each study likely results in widely
differing amounts of antigen available to the AT2s for processing and presentation,
and also depends on the analysis of distinct epitopes of interest between studies. In
none of these studies was antigen availability to AT2s directly quantified, and only one
report assessed AT2 MHCII presentation in the context of more than one antigen
system (two epitopes total, one from each system) [107]. In summary, the conflicting
nature of prior reports of AT2 MHCII function likely results from heterogeneity in all of
these respects.
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In our work, we have attempted to rigorously address all of these potential
experimental caveats and shortcomings, and using multiple orthogonal approaches,
we have demonstrated that AT2s exhibit inefficient MHCII presentation. This limited
MHCII presentation capacity by AT2s is consistent with the relatively modest impact
that loss of AT2 MHCII has in vivo described in chapter 3. However, it is surprising
given that AT2s seem to possess many promising MHCII+ APC characteristics, as
outlined in chapter 2, which should theoretically render them capable of robust MHCII
antigen presentation. In the next chapter, I will discuss possible mechanisms
restricting AT2 MHCII presentation and will offer our perspective on its why such
limited presentation might be favorable in AT2s.
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CHAPTER 5:
DISCUSSION AND FUTURE DIRECTIONS
AT2s were first described to express MHCII at homeostasis decades ago.
Despite this expression being highly unusual behavior for non-professional APC, let
alone a cell that ostensibly is not part of the formal immune system, very few reports
over the last 30 years have sought to understand the biological function of MHCII on
AT2s, and none has explored the mechanisms controlling AT2 MHCII expression. To
expand our understanding of AT2 MHCII regulation and function, in this dissertation I
have examined the factors driving steady-state AT2 MHCII expression, the role of
AT2 MHCII in vivo at homeostasis and during respiratory viral infection, and the
MHCII antigen presentation capacity of AT2s.
In chapter 2, I investigated the mechanisms driving AT2 MHCII expression
and also assessed other APC characteristics of AT2s. I demonstrated that AT2s
produce their own MHCII protein and that this expression is dependent on the CIITA
pIV transcription factor. I further showed that, contrary to convention, AT2 MHCII
expression does not require IFNg, nor does it require a number of other broad
inflammatory signals including the microbiota. I also found that AT2s possess ample
APC characteristics aside from constitutive MHCII expression: they are capable of
exogenous protein uptake and endogenous antigen expression, they possess
functionally competent classical antigen processing mediators, and they express
non-canonical costimulatory molecules. Altogether, I demonstrated that AT2s have
the potential to be robust MHCII+ APCs both at homeostasis and during infection.
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Based on these promising MHCII+ APC characteristics, in chapter 3, I sought
to elucidate the in vivo function of AT2 MHCII. I found that loss of MHCII from AT2s
did not result in clinical or histological lung disease at homeostasis. However, in
aged mice, the absence of AT2 MHCII resulted in changes to the homeostatic lung T
cell compartment; higher proportions of lung T cells were naïve, and lower
frequencies were antigen-experienced, compared to controls. Furthermore, I
demonstrated that in the setting of lower respiratory tract viral infection, mice lacking
MHCII on AT2s exhibited greater mortality and weight loss compared to controls.
However, the impacts at homeostasis and during infection were relatively modest,
and less than expected based on the magnitude of AT2 MHCII expression and
abundance of AT2s in the lung.
In chapter 4, I examined the MHCII antigen presentation capabilities of AT2s.
I demonstrated that AT2s are capable of processing and presenting both viral and
self protein antigens via MHCII, but their presentation capacity is substantially limited
compared to that of professional APCs, even when they have access to significantly
more epitope source protein and express similarly high levels of MHCII.
Furthermore, I found that in some cases, AT2s even failed to present synthetic
peptides. Thus, I found that AT2s exhibit globally restrained MHCII antigen
presentation capacity, which is consistent with the more measured contribution they
make via MHCII at homeostasis and to the outcome of lung viral infection as
observed in chapter 3.
Below I discuss the implications of these findings and provide insight into key
future areas of study.
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5.1 Constitutive MHCII expression paired with restrained antigen presentation:
a model for AT2 MHCII function tailored to the unique requirements of the lung
Despite constitutively expressing high levels of MHCII protein similar to
professional APCs (chapter 2), the MHCII antigen presentation capacity of AT2s is
substantially limited in comparison (chapter 4). At first glance, it seems that AT2s
thus exhibit an opposing and counterproductive combination of features. However, I
suggest that this particular configuration – of high MHCII expression and restricted
antigen presentation – is advantageous and specifically tailored to the unique
immune environment of the lung, where excessive T cell activation would be
especially damaging in comparison to other organs.
In this model, high MHCII expression poises AT2s to amplify lung adaptive
immune responses, but restricted MHCII presentation establishes a higher threshold
that must be overcome in order to do so. Such a system would enable MHCII
presentation by AT2s to trigger cognate T cell activation only in the setting of high
antigen burden, such as a severe lung infection, but would prevent excessive AT2induced amplification of T cells in response to continuous low levels of inhaled
innocuous environmental antigens, avoiding what would otherwise be constant
inflammatory lung damage. Furthermore, even in the setting of high antigen burden,
restrained presentation would ensure that AT2s amplify T cell responses in a more
tempered way to prevent excessive inflammation in the lung tissue. Although not
explored here, this model would suggest that just as the loss of AT2 MHCII resulted
in worse outcomes after viral infection, artificially increasing AT2 MHCII presentation
to DC-like levels would presumably also have a detrimental effect. In summary, I
propose that AT2s possess a unique combination of APC characteristics that are
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optimized specifically for their organ of residence, to enhance lung immune
responses but prevent immunopathologic destruction of the delicate gas exchangesurface that is necessary to sustain life. Overall, this results in a more measured
contribution of AT2 MHCII to immune responses in the lung, as demonstrated in
chapter 3.

5.2 Possible contributors to poor MHCII antigen presentation by AT2s
I demonstrated in chapter 4 that AT2s exhibit globally impaired capacity to
process and present antigen via MHCII. This suggests that AT2s possess impairments
in one or more of the key APC requirements detailed in 1.6: antigen uptake,
proteolysis, appropriate peptide and MHCII trafficking, and peptide loading.
AT2s have intact mechanisms of antigen uptake. As demonstrated in Fig 2.7,
AT2s are capable of endocytosing exogenous antigen, and overall they have robust
endocytic mechanisms by virtue of their surfactant recycling function [111]. AT2s also
expressed high levels of the endogenous self and viral proteins containing the
epitopes whose presentation I measured specifically (Figs 4.2, 4.4, 4.6), and in
general as the main targets of a variety of lung viral infections [182, 183], they likely
produce abundant endogenous antigens in those cases as well.
AT2s also have robust enzymatic processing capacity. They express a number
of enzymes in the endosomal network that are critical for the appropriate proteolytic
processing of surfactant proteins, such as Cathepsin H [114, 184]. They also express
conventional proteases that have been implicated in classical MHCII antigen
presentation. For example, either Cathepsin S or L can mediate the final steps of
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invariant chain processing into the CLIP peptide remnant and are important for antigen
processing, and AT2s express Cathepsin L [24-26, 185]. They also express the
asparagine endopeptidase (AEP), and the reducing enzyme gamma-interferoninducible lysosomal thiol reductase (GILT), both of which play key roles in the
generation of antigenic epitopes and in the maturation of other antigen processing
proteases and components [46, 76, 186-189] (Fig 5.1).
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Figure 5.1: AT2s express proteases associated with antigen processing and presentation.
Cathepsin H (Ctsh), Cathepsin S (Ctss), Cathepsin L (Ctsl), AEP (Lgmn), and GILT (Ifi30),
transcript abundance measured by bulk RNA-seq, normalized by RPKM, in AT2s from naïve 4
week old B6 mice. The results shown here are in whole based upon data deposited on the
LungMAP Consortium by J. Whitsett and Y. Xu. They were downloaded from (www.lungmap.net),
on Nov 18, 2018. The LungMAP consortium and the LungMAP Data Coordinating Center
(1U01HL122638) are funded by the National Heart, Lung, and Blood Institute (NHLBI).

I also showed that AT2s express the conventional MHCII-associated antigen
presentation mediators H2M and invariant chain (Figs 2.8, 2.9). While these mediators
are not required for the MHCII presentation of all epitopes, their presence strongly
suggests that AT2s have intact MHCII trafficking and peptide loading mechanisms. I
found that AT2s express only one heterodimeric isoform of H2M, H2Mab1, in contrast
to conventional potent APCs, such as B cells and DCs, which also express H2Mab2
(Figs 2.9, 2.10, 2.12). This led us to speculate that limited antigen presentation by
AT2s might result from functional inferiority of H2Mab1 as compared to H2Mab2.
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However, consistent with prior reports [149, 150], I demonstrated that the H2Mab1
was capable of enabling complete CLIP removal (Fig 2.9), and of facilitating Ea52-68/IAb complex formation (Fig 4.6).
Thus, AT2s appear to possess all of the requisite MHCII+ APC capabilities and
do so robustly. However, they nonetheless exhibit restricted presentation. This is
highly unusual; in prior studies, the Eisenlohr laboratory has found that simply
transducing skin fibroblasts with CIITA, which induces expression of MHCII, invariant
chain, and H2M, is enough to render them highly presentation competent [46]. Overall,
this suggests that there may be mechanisms operating in AT2s that actively oppose
MHCII presentation.
The endosomal network of AT2s is highly specialized for the synthesis,
secretion, and recycling of surfactant [114], as discussed in 1.8. Thus, although AT2s
have intact endocytic and proteolytic mechanisms that can facilitate MHCII antigen
presentation, as well as appropriate MHCII trafficking and peptide loading mediators,
it is possible that their endosomal compartments are so tailored toward surfactant
production that they are dominantly incompatible with the trafficking, localization, and
degradation requirements for optimal MHCII presentation. For example, it is possible
that the proteolytic environments that enable proper surfactant pro-protein processing
or degradation are too harsh for the preservation of antigenic epitopes, and thus the
majority of candidate peptides are destroyed before loading. It is also conceivable that
the endosomal maturation and trafficking pathways optimized for delivery of surfactant
components to the lamellar body may prevent the efficient transport of antigenic
peptides to MHCII-containing intracellular compartments.
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It is also unusual that AT2s express such high levels of MHCII yet present only
some synthetic peptides when provided exogenously (Fig 4.1). One possible
explanation is that AT2 MHCII molecules are already bound to a high affinity peptide
on the cell surface that can be displaced only by even higher affinity peptides. If such
a peptide loads onto MHCII during the early stages of intracellular MHCII biosynthesis
and trafficking, this would explain the poor presentation of protein-derived peptides by
AT2s as well. One appealing candidate is a surfactant protein derived peptide, such
as a pro-SP-C or pro-SP-B processing remnant, which would be abundant and present
in the endosomal compartments where nascent MHCII molecules transit and peptideloading generally occurs.
Understanding the factors limiting AT2 presentation will be an important area
of future inquiry, and MHCII peptide elution studies are ongoing in order to investigate
this latter hypothesis.

5.3 Drivers of constitutive MHCII expression by AT2s
I was unable to identify an immune signal required for AT2 MHCII expression
despite investigating the conventional IFNg axis as well as a variety of broad
adaptive and innate mediators, including the microbiota. Although I did not examine
every possibility, this strongly suggests that MHCII expression is not driven by
inflammation. Publicly available single cell RNA-sequencing data suggest that AT2
MHCII expression is undetectable during embryogenesis and increases only after
birth (Fig 5.2). Thus, it is possible that AT2 MHCII expression is induced and
sustained by a non-immune environmental stimulus, for example, mechanical stretch
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or a gaseous component of inhaled air, or is simply an intrinsic part of the AT2 cell
developmental identity.
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Figure 5.2: AT2s upregulate MHCII expression after birth. Expression of MHCII a and b chain
(H2-Aa and H2-Ab1) transcripts measured by single cell RNA-seq in AT2s from mice on the
embryonic or post-natal days indicated. The results shown here are in whole based upon data
deposited on the LungMAP Consortium by J. Whitsett, B. Aronow, and S. Potter. They were
downloaded from (www.lungmap.net), on June 26, 2020. The LungMAP consortium and the
LungMAP Data Coordinating Center (1U01HL122638) are funded by the National Heart, Lung,
and Blood Institute (NHLBI).

I identified the CIITA pIV isoform as the main transcriptional driver of AT2
MHCII expression; thus, in future work, I seek to determine the specific transcription
factors that in turn initiate AT2 CIITA pIV recruitment in AT2s. The three transcription
factors that have been described to bind to CIITA pIV are STAT1, IRF1, and USF1.
USF1 is ubiquitously expressed; STAT1 is induced downstream of IFNg and then in
turn induces expression of IRF1 [58]. However, I demonstrated that AT2 MHCII
expression is independent of IFNg and STAT1 (Figs 2.4, 2.5). Since IRF1 is induced
by STAT1, this suggests that AT2 pIV recruitment operates independently of both
IRF1 and STAT1. Future studies will investigate the requirement of USF1, although it
seems unlikely that USF1 alone would be sufficient to initiate transcription. Thus,
future work will also seek to identify other transcription factors and their DNA binding
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sites that mediate CIITA pIV transcription in AT2s. As AT2 MHCII is lost in mice
lacking an 800bp segment encompassing the CIITA pIV promoter region (STAT1,
IRF1, and USF1 binding sites), transcription start site (TSS), and first exon [58, 146],
initial bioinformatics approaches will be used to identify candidate transcription factor
motifs in this promoter region. However, since this 800 bp deletion does encompass
the TSS, it is not possible to determine whether the relevant regulatory element is
contained in this deletion as well. Thus, if initial studies of the DNA elements limited
to this promoter region are not fruitful, I would expand my search to include the
possibility of more distal regulatory DNA elements and candidate binding
transcription factors.
Once the DNA regulatory elements and transcription factors are identified, it
will also be of interest to determine whether AT2s share a similar transcriptional
pathway with TECs and ILC3s, the other two cell types that exhibit IFNg independent
but CIITA pIV dependent expression of MHCII; the mechanistic drivers of CIITA pIV
expression in ILC3s and TECs are still not understood.

5.4 Polarity of MHCII expression by AT2s
One aspect of AT2 MHCII expression that warrants further study is the
surface localization of MHCII. As AT2s are polarized cells, they bear an apical
membrane that is directed into the alveolar space, and a basolateral surface that
borders the interstitium. Understanding the localization of MHCII on AT2s will
provide valuable insight into its function. For example, if MHCII is pointed into the
interstitium where it would be far more likely to encounter a CD4+ T cell, especially at
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homeostasis, this would support a stronger function for AT2 MHCII in regulating T
cell function on a frequent basis. In contrast, if AT2 MHCII is pointed into the alveolar
space, this would suggest MHCII presentation to CD4+ T cells that is limited primarily
to situations of substantial inflammation where more T cells infiltrate the alveolar
spaces. Although I did examine AT2 MHCII expression in situ via
immunofluorescence microscopy, the techniques I used were not sufficient to
determine the polarity of AT2 MHCII. Higher resolution imaging studies will be
necessary to resolve this, at a minimum confocal microscopy and possibly immunoelectron microscopy.

5.5 The possibility of novel functions of MHCII on AT2s
Publicly available bulk RNA-sequencing data of 4 week old mouse AT2s
demonstrates that invariant chain and MHCII transcripts are some of the most highly
expressed transcripts in AT2s; in terms of relative abundance, invariant chain (Cd74)
is #16 and MHCII (H2-Aa) is #32 overall out of more than 20,000 transcripts
measured (Table 5.1). This observation combined with such high levels of MHCII
protein on AT2s that appear to be constitutive and inflammation-independent led me
to wonder whether MHCII serves another key function in the basic biology of AT2s,
besides interacting with CD4+ T cells.
To this end, I asked whether MHCII was required for two critical functions of
AT2s: regenerative capacity and surfactant production. I directly assessed their stem
cell like function and found that loss of MHCII did not affect their capacity to generate
organoids in vitro (Fig 3.10). Although surfactant production was not directly
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assessed, if surfactant biosynthesis or secretion were substantially disrupted, then
mice lacking MHCII on AT2s would experience severe respiratory failure and
disease at homeostasis, which I did not observe either clinically or histologically (Fig
3.9). Thus, MHCII does not appear to be absolutely required for either of these two
main AT2 functions, but further studies are necessary to determine whether MHCII
makes a smaller contribution or serves another function in AT2s outside of these
two.

Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Gene ID
Sftpc
Scgb1a1
Rn45s
Lyz2
Sftpa1
Cxcl15
Malat1
Sftpb
Cbr2
Slc34a2
Lars2
Scd1
Lyz1
Rpl10
Tmsb4x
Cd74
Wfdc2
Sod1

RPKM
24084.6
18103.7
5978.34
5809.2
1899.89
1820.24
1711.24
1325.51
1169.95
1114.85
981.425
936.29
716.109
447.74
440.907
438.262
384.277
382.71

Rank
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Gene ID
Rpl41
Cyp2f2
Lamp3
Chil1
Scgb3a2
Actb
Hc
Hspa8
Eef1a1
Ftl1
Sftpd
Tpt1
Atp1b1
H2-Aa
Rps23
S100a11
Scgb3a1
S100g

RPKM
349.927
343.48
334.136
313.113
302.334
294.986
275.855
275.259
263.356
263.086
260.039
242.97
236.5
214.948
210.497
206.536
203.18
196.786

Table 5.1: MHCII and invariant chain transcripts are among the most highly abundant in
AT2s. Abundance of the transcripts indicated, measured by bulk RNA-seq, normalized by
RPKM, in AT2s from naïve 4 week old B6 mice. Highlighted are MHCII (H2-Aa) and invariant
chain (Cd74) transcripts. The results shown here are in whole based upon data deposited on the
LungMAP Consortium by J. Whitsett and Y. Xu. They were downloaded from
(www.lungmap.net), on Nov 18, 2018. The LungMAP consortium and the LungMAP Data
Coordinating Center (1U01HL122638) are funded by the National Heart, Lung, and Blood
Institute (NHLBI).
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Another possibility is that MHCII expression is simply a byproduct of its
coordinated expression with the other CIITA-dependent genes, which instead might
play the more important role in AT2s at homeostasis. One candidate is invariant
chain, which has been reported to perform several functions outside of chaperoning
MHCII [190]. Invariant chain is typically synthesized in molar excess of MHCII and
thus can reach the cell surface without being associated with MHCII or degraded to
CLIP peptide; indeed, it is detectable on the surface of AT2s [191]. Previous studies
have demonstrated that surface invariant chain can serve as a receptor for the
pleiotropic cytokine MIF-1 [192], and one group has demonstrated this specifically in
AT2s, suggesting that it may contribute to lung epithelial repair [191]. Globally Cd74deficient mice do not exhibit overt lung disease, suggesting that if invariant chain
does play an alternative role in AT2s, it is not strictly required for their life-sustaining
functions, similarly to MHCII.
In general, much more extensive characterization of AT2 function,
proliferation, survival, gene and protein expression, and more, are needed to
investigate whether there are other non-immunologic processes that are disrupted
by the loss of MHCII and or associated genes in AT2s.

5.6 The potential role of AT2 MHCII in other immune settings
I found that the loss of AT2 MHCII resulted in subclinical changes to the
proportions of naïve, activated, memory, and regulatory phenotype T cells in the
lungs of aged mice. Specifically, in 14-month-old mice lacking AT2 MHCII, a higher
proportion of lung CD4+ and CD8+ T cells remained naïve, compared to control mice
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that had higher proportions of activated, effector memory, and regulatory T cells. As
discussed in chapter 3, this suggests that AT2 MHCII presentation enhances the
antigen encounter of lung CD4+ T cells at homeostasis, supporting the formation of a
variety of antigen-experienced CD4+ and CD8+ T cell subsets.
The majority of studies of other atypical MHCII+ cells suggest that their MHCII
expression plays a tolerogenic role at homeostasis. For example, mice lacking
MHCII on all nonhematopoietic cells [92], or just on ILC3s [90], demonstrate
increased frequencies of effector memory T cells at homeostasis. Thus, I was
surprised to find that loss of AT2 MHCII resulted in a decrease in effector memory T
cells, rather than an increase. As I observed decreases in both effector memory T
cells and regulatory T cells in SPCDAb1 mice, this suggests that the role of AT2 MHCII
at homeostasis is more mixed and may promote both T cell activation as well as
tolerance and Treg formation depending on the situation.
The ultimate importance of AT2 MHCII regulation of lung T cells at
homeostasis is still unclear, given that its impact was small and only apparent in
aged 14-month-old mice, but not 7-month-old adult mice. Furthermore, the mice did
not exhibit any signs of lung disease upon loss of AT2 MHCII clinically or when
measured histologically in 9-month-old mice. It is possible that the contribution of
AT2 MHCII in vivo at homeostasis to lung T cells is indeed minor and is dispensable
for a functionally intact lung immune environment. However, it is also possible that
the homeostatic importance of AT2 MHCII may have been underestimated in our
experiments, as discussed in chapter 3 and below.
The fact that loss of AT2 MHCII did not result in overt lung disease at
homeostasis was surprising for a few reasons. The first is that the constitutive and
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high levels of MHCII expressed by AT2s, independent of inflammation, strongly
suggests that AT2 MHCII serves an important function in preventing disease at
steady state; if only important during inflammation, then presumably AT2s would
instead behave like all other nonhematopoietic cells and only upregulate MHCII in
response to IFNg. The second is that homeostatic AT2 MHCII expression in naïve or
healthy lungs seems to be evolutionarily conserved, at least between rodents and
human, based on prior reports and our own findings, as demonstrated in chapter 2.
I also found that MHCII expression by naïve AT2s is conserved across commonly
used mouse strains C57Bl/6, BALB/c, and C3H (Fig 5.3). Consistent with a prior
report [105], I did find that AT2s from one mouse strain, A/J, do not express MHCII; I
will discuss the possible implications of this below. Thirdly, the two cell types that
have IFNg-independent, CIITA pIV-dependent MHCII induction mechanisms similar
to AT2s – TECs and ILC3s – play critical roles at homeostasis in central T cell
development and peripheral selection to prevent immunodeficiency, autoimmunity,
and pathologic anti-commensal responses. Mice lacking MHCII on ILC3 develop
spontaneous intestinal disease [90], and the absence of TEC MHCII results in the
failure of CD4+ T cell positive selection [87], resulting in severe immunodeficiency.
Thus, I had hypothesized that AT2 MHCII might play an equally critical role at
homeostasis. Although I did not observe such an overt disease-protecting function
for AT2 MHCII at homeostasis in our mice housed under SPF conditions, a role may
be more evident in humans or in wild mice that are exposed to a much larger
repertoire of inhaled antigens and microbes and have a dramatically different, “less
naïve” immune system [177, 193-195]; in this setting, the AT2 MHCII-induced
increase in antigen-experienced lung T cells that I observed could have larger
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clinical consequences. Furthermore, as discussed in chapter 3, it is also possible
that in mice of more advanced age, beyond 9 months, histological lung disease may
become more apparent, even under SPF conditions.
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Figure 5.3: Homeostatic AT2 MHCII expression is conserved across multiple mouse strains
but is absent in A/J mice. MHCII protein expression by AT2s from naïve C57Bl/6 (B6) wild-type
(WT) and MHCII-/- mice, as well as WT BALB/c, A/J, and C3H mice, shown in the colors indicated.
Expression was measured by flow cytometry using a pan I-A/I-E antibody; the allele that the
antibody binds to in each strain is listed above each plot. Histograms depict n=2-3 mice per strain.
Differences in overall MFI between strains are not necessarily reflective of differences in
magnitude of expression, since the antibody may have different affinities for each MHCII allele.

I also explored the role of AT2 MHCII in the setting of a primary immune
response to respiratory viral infection. While loss of MHCII on AT2s did result in an
increase in disease severity, the impact was modest (Fig 3.11). While the factors
responsible for this AT2 MHCII protective effective are not yet characterized, the
most likely mechanism is CD4+ T cell-mediated. Therefore, the moderate clinical
effect of AT2 MHCII loss that I observed could reflect an equally modest impact on
the CD4+ T cell response; in prior sections I have suggested that this is due to
inefficient MHCII antigen presentation by AT2s. However, it could also reflect the fact
that CD4+ T cells, while critical for optimizing the immune response, are also not
absolutely required for successful viral clearance or eventual clinical recovery during
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primary influenza or Sendai virus infections in mice [166, 168-171]. Thus, a primary
influenza or Sendai virus infection model may not be the scenario in which the
possible contributions of AT2 MHCII would be the most overtly clinically evident or
immunologically impactful. Thus, in ongoing and future studies I aim to understand
the contribution of AT2 MHCII in other disease settings.
The contribution of primary infection-induced CD4+ T cells is far more evident
clinically during a subsequent secondary infection. Mice lacking CD4+ T cells during
a primary infection demonstrate severely impaired B cell responses, limiting the
development of neutralizing antibodies, and also exhibit poor formation of memory
CD8+ T cells [162, 163, 171, 196, 197]. Therefore, upon secondary challenge, these
mice have impaired antibody-mediated protection and inferior capacity to clear the
virus compared to wild type mice. Thus, a secondary infection challenge model
would be a clearer way to study the clinical impacts of a potentially impaired CD4
response generated during primary flu or Sendai virus infection of SPCDAb1 mice.
I am also interested in understanding whether AT2 MHCII affects the
development of virus-specific CD4+ memory T cells, as they correlate with
heterosubtypic protection in humans [198]. Prior studies from the Swain laboratory
suggest that robust influenza-specific memory CD4+ T cell formation requires two
cognate TCR-MHCII encounters: the first priming interaction in the lymph node, and
a second around days 5-7 post-infection [124, 199]. The precise location of this
second MHCII/antigen encounter is unknown, but as MHCII+ AT2s are present at the
site of infection where there would be available antigen and antigen-specific CD4+ T
cells, it is possible that AT2s deliver this second checkpoint and contribute to the
optimal development of memory CD4+ T cells. It is also possible that local MHCII
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antigen presentation by AT2s helps to facilitate the development and retention
specifically of the tissue-resident subset of memory CD4+ T cells (Trm) [200-202].
The impact of AT2 MHCII on the development of antigen-specific CD4+ Trm is of
particular interest, as CD4+ Trm can mediate protection upon viral challenge [203].
Other lung disease models in which AT2 MHCII may serve an important
function are those in which CD4+ T cells play a more direct protective or pathologic
role. These include models of allergic asthma, in which Th2 phenotype CD4+ T cells
contribute to airway inflammation directly via the production of the inflammatory
cytokines IL-4, IL-5, and IL-13 [204]. CD4+ T cells also play a primary role in the
pathogenesis of lung hypersensitivity pneumonitis, where repeated exposures to
inhaled organic antigens leads to lymphocytic alveolitis, granulomatous
inflammation, and progressive lung fibrosis [205-207]. AT2 MHCII could either help
to protect against these diseases or worsen them. It is possible that AT2 MHCII
helps to suppress these responses by inducing tolerance of naïve T cells to such
allergens or environmental antigens; however, it is possible that activation of CD4+ T
cells by AT2 MHCII antigen presentation contributes to the amplification of this
immune pathology. It is also possible that AT2 MHCII can perform both of these
tasks under different circumstances, and a switch in these functions contributes to
the development of disease. For example, in healthy individuals with no allergy or
hypersensitivity, AT2 MHCII tolerization of CD4+ T cells operates unperturbed.
However, in situations of allergy, where inappropriate CD4+ T cell responses have
been primed and expanded, or in hypersensitivities where large amounts of antigen
are present in the alveolar spaces, these tolerance mechanisms may be overridden,
with AT2 MHCII presentation to CD4+ T cells instead resulting in disease.
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Preliminary data indicates that AT2 MHCII may contribute to protection in the setting
of ova-induced murine asthma, in that mice lacking MHCII on AT2s exhibit modestly
higher frequencies of Th2-cytokine producing CD4+ T cells and higher numbers of
lung eosinophils (Fig 5.4); however, additional studies are needed to corroborate
this, including those that measure the symptomatic implications of such changes,
such as airway hyperresponsiveness.
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Figure 5.4: SPCDAh1 mice exhibit cellular signs of increased allergic phenotype compared
to Ab1fl/fl control mice in an inhaled ova allergy model. a-g, Comparison of Ab1fl/fl and SPCDAb1
mice after ova/alum sensitization followed by intranasal ova challenge. a-c, Numbers of all cells
(a), eosinophils (b), and T cells (c) in the BAL; n=4-6 mice per strain for Ab1fl/fl and SPCDAb1 mice,
with n=1 naïve B6 control mouse control. d-g, Proportion of lung CD4+ T cells secreting IL-5 (d),
IL-13 (e), IL-17 (f), and IFNg (g), after PMA/Ionomycin restimulation; n=6 mice per strain for Ab1fl/fl
and SPCDAb1 mice, with n=1 naïve B6 control mouse control. a-g, Data are mean plus SEM from
one experiment.

Other disease models of interest stem from previous studies of A/J mice; as
AT2s in A/J mice do not express MHCII, they represent another model in which to
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assess the outcomes of loss of AT2 MHCII. A/J mice are highly susceptible to
developing spontaneous and carcinogen-induced tumors of AT2 cell origin [208],
suggesting that the lack of AT2 MHCII may impair cancer-specific immune
responses in the lung. AT2s also experience particularly severe respiratory virus
disease compared to other conventional mouse strains [209], and of particular
interest at this time, they are one of the few strains of inbred mice that are
susceptible to pulmonary disease after infection with intranasal murine hepatitis
virus-1 (MHV-1), a mouse betacoronavirus in the same family as SARS-CoV2 [210].
As A/J mice also bear other immune-related defects, it is of great interest in future
work to determine whether the absence of AT2 MHCII directly contributes to worse
coronavirus disease and more facile cancer development in these mice [211].
Finally, it will be an essential avenue of future work will also be to understand
how our current and future findings in mice translate to human lung immunity. In
particular, I seek to understand whether alterations in AT2 MHCII expression or
function contribute to the wide variation in outcome of infectious and immunologic lung
diseases in humans. Given the current worldwide Covid-19 pandemic, I am also
particularly interested in whether AT2 MHCII contributes to protection or to the
outcome of disease in the setting of SARS-CoV-2 infection; as AT2s are the main cell
type infected with this virus in the human lung parenchyma [212-214], they may
contribute to SARS-CoV-2 specific CD4+ T cell responses via endogenous MHCII
antigen presentation.
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5.7 Concluding remarks: why do AT2s express MHCII?
A central question underlying this work is, teleologically, why would AT2s
“need” to express MHCII? Or framed another way, given the expansive and intricate
network of conventional immune cells and specialized immune organs that comprise
the formal immune system, why would the lower respiratory tract have evolved to
also have its own parenchymal cells constitutively express MHCII?
The most straightforward explanation is that this provides an additional
mechanism to further tailor the adaptive immune response based on the structural
and functional constraints of the lung. The respiratory tract is a barrier site, and thus
is constantly faced with both innocuous and potentially harmful insults. It is also a
location where having excessive cellular infiltration and inflammation is particularly
dangerous and often has lethal consequences. As most immune cells, in particular T
cells, are circulatory, they migrate throughout various organs to exert their effector
functions without necessarily intrinsically discriminating based on anatomic location
per se. Having a local and lung-specific MHCII-expressing cell that is specifically
adapted to regulate these responses, to facilitate rapid infection resolution but spare
the delicate gas-exchange surface, would be enormously beneficial. AT2s are highly
abundant in the lung parenchyma, and they are poised anatomically at the air/tissue
interface, making them uniquely situated to respond to foreign substances that reach
the alveolar spaces. Furthermore, they are replete with their own specialized set of
intracellular machinery, and they are preferentially infected by a variety of
pathogens, endowing them with unique antigen processing and presentation
characteristics in comparison to conventional APCs. Thus, AT2s are prime
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candidates for contributing to this crucial tissue-specific immune regulation in the
lung via MHCII.
Over the last decade or so, the study of immunology in peripheral tissues,
rather than in the blood and secondary lymphoid organs, has become more
commonplace. Furthermore, the importance of contributions made by stromal and
parenchymal cells to shape these immune responses based on organ-specific
considerations has been increasingly appreciated [215, 216]. Here I propose that
AT2 cells, by virtue of their constitutive MHCII expression and restrained MHCII
antigen presentation, contribute to the regulation of local immune responses in the
lung. It is our hope that future studies will build upon our initial findings to elucidate
roles for AT2 MHCII antigen presentation in other situations of homeostasis and
disease, adding to our basic understanding of the exquisite complexities of how
adaptive immune responses are regulated in situ.
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CHAPTER 6:
MATERIALS AND METHODS

Mice
C57Bl/6 wild-type (B6), B6.129S2-H2dlAb1-Ea/J (MHCII-/-) [217], B6;129S4-H2DMatm1Luc/J (H2-DMa-/-) [29], B6.129S7-Ifngtm1Ts/J (Ifng-/-) [218], B6.129S(Cg)Stat1tm1Dlv/J (Stat1-/-) [219], C.129S2(B6)-Ciitatm1Ccum/J (Ciita-/-) [54, 220], B6.SJLPtprca Pepcb/BoyJ (CD45.1 B6), B6.129X1-H2-Ab1tm1Koni/J (H2-Ab1fl/fl) [158], as well
as C3H, A/J, BALB/c, and CB6F1/J (F1 [BALB/c x C57Bl/6] mice were originally
purchased from the Jackson Laboratory. C57Bl/6 Cd74-/- mice [20] were originally
provided by Guo-Ping Shi (Harvard), and C57Bl/6 Ciita pIV-/- mice [146] were provided
by S. Hugues (University of Geneva). C57Bl/6 SPC-Cre-ERT2 mice [157] were
provided by G.S. Worthen, B6.129S7-Ifngr1tm1Agt/J (Ifngr1-/-) [221], B6(Cg)Ifnar1tm1.2Ees/J (Ifnar1-/-) [222], and B6.Cg-Ifngr1tm1Agt Ifnar1tm1.2Ees/J (Ifnar1-/-Ifngr1-/-)
mice were provided by E. Behrens, and germ-free mice were provided by M. Silverman
(Children’s Hospital of Philadelphia). C57Bl/6 B6.129P2(SJL)-Myd88tm1.1Defr/J (Myd88/-

) mice [223] were provided by S. Shin, and B6.129S2(C)-Stat6tm1Gru/J (Stat6-/-) mice

[224] were provided by C. Hunter (University of Pennsylvania). All mice were
maintained in specific pathogen-free facilities at the Children’s Hospital of
Philadelphia, except for Myd88-/- and Stat6-/- mice, which were housed in specific
pathogen-free facilities at the University of Pennsylvania, and germ-free mice, which
were housed in gnotobiotic mouse facilities at the University of Pennsylvania. Mice
were age and sex matched for all studies. 8-12 week old mice were used for all
experiments except where indicated in the text.

All animal procedures were in
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compliance with institutional and AAALAC ethical guidelines and were approved by
the Institutional Animal Care and Use Committee (IACUC) at the Children’s Hospital
of Philadelphia.

Cell lines
The B6 primary skin fibroblast cell line was derived in our laboratory and has
been described previously [225]; it was maintained in Dulbecco’s Modified Eagle
Medium (DMEM) containing 5% FBS, Penicillin-Streptomycin, and 2mM L-glutamine.
Madin-Darby canine kidney (MDCK) cells were provided by S. Hensley (University of
Pennsylvania) and were maintained in MEM with 10% FBS. Monkey kidney LLC-MK2
cells were provided by Carolina Lopez (University of Pennsylvania) and were
maintained in DMEM with 10% heat-inactivated FBS, Penicillin-Streptomycin, 2 mM
L-glutamine, and 1 mM sodium pyruvate. T cell hybridoma lines were derived in our
laboratory and have been described previously [46, 178]; these were maintained in
“complete RPMI” media: RPMI media containing 10% FBS, 50 µM 2-mercaptoethanol,
Penicillin-Streptomycin, 2mM L-glutamine.

Viruses
Mouse lung-adapted H1N1 influenza A virus, A/Puerto Rico/8/1934 (IAV PR8),
was originally provided by C. Lopez (University of Pennsylvania), and then expanded
in 10-day-old embryonated chicken eggs. IAV PR8 viral titer was determined by
standard focus-forming unit (FFU) assay in MDCK cells. Sendai virus, strain 52 (SeV
52), was also a generous gift of C. Lopez (University of Pennsylvania). SeV 52 viral
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titer was determined using a tissue culture infectious dose (TCID50) standard infectivity
assay in LLC-MK2 cells.

Synthetic peptides
The

following

(RSWSYIVETPNSENGIC),

synthetic
NA161-175

used:

HA91-107

(SVAWSASACHDGMGW),

HA302-313

peptides

were

(CPKYVRSAKLRM), HA107-119 (SVSSFERFEIFPK), NA79-93 (IRGWAIYSKDNSIRI). All
peptides were obtained at >85% purity from Genscript.

Tissue isolation for in vitro analysis and flow cytometry
For isolation of AT2 cells, the lung vasculature was first perfused with 5 mL
PBS by injecting into the cardiac right ventricle. Lungs were then inflated via
intratracheal instillation of 0.9 mL AT2 digest media [5 U/mL Dispase (354235,
Corning), 1.66 mg/mL Collagenase A (10103586001, Sigma), 0.33 mg/mL DNase I
(10104159001, Sigma) in PBS]. The trachea was then tied with suture to keep the
lungs inflated while they were excised en bloc and then placed in an additional 1 mL
digest media, then incubated at 37°C. After 45 minutes, 5 mL 20% FBS in PBS was
added, and the parenchymal lung lobes were removed from the large airways with
forceps, then dissociated by vigorous pipetting. Digested lungs were passed through
a 70 µm strainer, incubated in ACK lysis buffer to remove RBCs, then passed through
a 40 µm strainer to obtain a single cell suspension.
For isolation of lung T cells, the lung vasculature was first perfused with 5 mL
1% FBS in PBS by injecting into the cardiac right ventricle. Individual parenchymal
lung lobes were removed from the chest cavity and placed into gentleMACS C tubes
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containing 2 mL 1% FBS in PBS. Lymphocyte digest media was then added to the
lungs (1% FBS, 2.25 mg/mL Collagenase D (11088866001, Sigma), 0.15 mg/mL
DNase I in PBS in 4 mL final volume), which were then gently disrupted using
gentleMACS homogenizer program m_spleen_01.01, then incubated for 45 minutes
at 37C with shaking. Complete RPMI media was then added to each tube, followed
by further dissociation using gentleMACS homogenizer program m_lung_02.01.
Digested lungs were then passed through a 70 µm strainer, incubated in ACK lysis
buffer to remove RBCs, then passed through a 40 µm strainer to obtain a single cell
suspension.
AT2s could not be recovered from the T cell digest; likewise, the AT2 digest
was not optimal for T cell isolation as it resulted in the degradation of surface CD4 and
CD8 from T cells. In some T cell isolation experiments, a small sample of AT2s was
also needed for the purposes of confirmation phenotyping to assess deletion or
presence of MHCII. In these cases, prior to the addition of lymphocyte digest media
to the lungs, a small ([<2mm]3) portion of lung was removed, and then incubated for 1
hour at 37C in 0.4 mL AT2 digest media. Next, 0.1 mL of FBS was added, and the
sample was then homogenized through a 40 µm cell strainer using the flat end of a 1
mL syringe plunger, to obtain a single cell suspension.
To harvest lungs for virus titering, lung lobes were removed directly from the
thoracic cavity (with no perfusion or instillation) and placed in gentleMACS M tubes
containing 1 mL PBS. Additional PBS was then added to each M tube to produce a
final 10% weight/volume solution of lungs/PBS. Lungs were then homogenized using
gentleMACS dissociator program RNA_01.01. Cellular debris was removed by
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centrifugation at 600xg for 10” at 4°C, and the clarified supernatant was then used for
virus titering.
For isolation of splenocytes, spleens were removed from the abdominal cavity
and placed directly in PBS. Spleens were then homogenized through a 70 µm cell
strainer using the blunt end of a 3 mL syringe plunger. The splenocytes were then
incubated in ACK lysis buffer to remove RBCs, then passed through a 40 µm strainer
to obtain a single cell suspension.
For isolation of immune cells from peripheral blood, blood was collected via
cheek bleed or IVC puncture into PBS containing 25 mM EDTA. Samples were
centrifuged at 300xg for 10”, followed by ACK lysis of the cell pellet to remove RBCs.
For isolation of bone marrow cells, whole bones of the hindlimb were removed
from mice. In a sterile manner, the ends of the bones were cut and the interior cavity
was flushed with PBS.
For isolation of BAL cells, the trachea was cannulated and flushed three times
with 0.7 mL of PBS containing 5% BSA, 2 mM EDTA, and complete Mini, EDTA-free
protease inhibitor cocktail (11873580001, Sigma). Each flush was collected separately
and kept on ice, then centrifuged at 6800xg at 4°C for 2 minutes. The supernatant was
removed and the cell pellets from all three flushes were combined, then incubated in
ACK lysis buffer to remove RBCs.
For isolation of human distal lung cells, healthy human lungs were obtained
with informed consent from the Prospective Registry of Outcomes in Patients Electing
Lung Transplant Study approved by University of Pennsylvania Institutional Review
Board in accordance with institutional ethical procedures and guidelines. The donor
used in this study had the following characteristics: 36 y.o. M, no smoking history, no
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evidence of active infection, P/F ratio of 346. Lungs were digested as described
previously by Zacharias and Morrisey [226]. Briefly, a 2x2 cm piece of distal lung tissue
(pleura and airways removed) was minced then processed in the same AT2 digest
media as above using a gentleMACS dissociator at 37°C for 35 minutes. Digested
lungs were washed, passed through 70 µm and 40 µm strainers, and then incubated
in ACK lysis buffer to remove RBCs and generate a single cell suspension.

Cell type identification via flow cytometry and cell sorting
All flow cytometry antibodies used are listed in Table 6.1. For all flow cytometry
experiments, unless otherwise stated, single cell suspensions were first stained for
dead-cell exclusion with Live/Dead Aqua (L34957, Thermo Fisher) in PBS, followed
by Fc-receptor blockade with anti-CD16/CD32 (553141, BD) for mouse cells or Human
TruStain FcX (422301, Biolegend) for human cells, in 0.1% BSA in PBS. Cells were
then stained with surface antibodies diluted in 0.1% BSA in PBS for 30” in the dark at
4°C. If necessary, cells were then fixed and permeabilized for intracellular staining
using the BD Cytofix/Cytoperm kit (554714, BD) or for intranuclear staining using the
eBioscience Foxp3/Transcription Factor Staining kit (00-5523-00, Thermo Fisher).
Intracellular and intranuclear stains were diluted in the corresponding kit wash buffer
and were incubated for 30” at room temperature. Flow cytometry data were acquired
on the following analyzers: LSRII and LSRFortessa (BD), CytoFLEX LX and
CytoFLEX S (Beckman Coulter). Cell sorting was performed on the following sorters:
FACSAria Fusion and FACSJazz (BD), and MoFlo Astrios (Beckman Coulter). All flow
cytometry analyses were conducted using FlowJo software (FlowJo LLC).
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Murine AT2s were identified by flow cytometry as detailed in Fig 6.1 [105]. In
studies where MHCII expression was evaluated, AT2s were identified using the gating
strategy without MHCII as a selection marker, as CD45-, CD31-, EpCAMint cells (Fig
6.1b). For all other flow cytometry studies, AT2s were identified as CD45-, CD31-,
EpCAM+ MHCII+ cells (Fig 6.1a). Both gating strategies were validating by intracellular
staining for pro-SPC (Fig 6.1c). Human AT2s were identified by flow cytometry as
detailed in Fig 6.2 as HT2-280+ lung cells [145], by staining with unlabeled anti-HT2280 followed by an anti-mouse IgM fluorophore-conjugated secondary antibody.
Other cell types were identified via flow cytometry as follows: Lung endothelial
cells (CD45-, CD31+), Lung CD103+ DCs (CD45+, CD11c+, CD103+), Lung alveolar
macrophages (CD45+, CD11c+, CD103-, CD11b-, CD64+), Splenic CD8+ DCs (CD45+,
CD11c+, CD3-, CD8+), B cells (FSC-Alow, CD45+, CD11c-, CD19+ or B220+), T cells
(CD45+ CD3+), CD4+ T cells (CD45+, CD3+, CD4+, CD8-), CD8+ T cells (CD45+, CD3+,
CD8+, CD4-), NK cells (CD45+, CD3-, NK1.1+), gd T cells (CD45+, CD3+, TCRd+),
neutrophils (CD45+, CD11c-, CD11b+, Ly6G+), and eosinophils (CD45+, CD11c-,
CD11b+, Ly6G-, SiglecF+).
For cell sorting experiments, samples were not stained with the Live/Dead
viability dye or Fc-receptor blockade to minimize sample processing time and preserve
cell viability. The following professional APC populations were sorted: qPCR DCs
(CD45+,CD11c+,MHCIIhi); DQ-ova assay DCs (CD45+, CD11c+, MHCIIhi) and B cells
(CD45+, B220+, MHCII+); C57Bl/6 hybridoma assay CD11c+/CD19+ APCs (CD45+,
MHCII+, CD11c+ or CD19+); Balb/c hybridoma assay CD11c+ APCs (CD45+, MHCII+,
CD11c+); ELISpot CD103+ DCs (CD45+, CD11c+, CD103+). The following AT2
populations were sorted: DQ-ova assay, qPCR, C57Bl/6 hybridoma assay and Balb/c
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hybridoma assay AT2s (CD45-, CD31-, EpCAM+, MHCII+), ELISpot AT2s (CD45-,
CD31-, EpCAM+), and AT2s for organoid culture (CD45-, CD31-, Podoplanin-, CD34-,
Sca1-, EpCAMint). Lung fibroblasts were sorted for organoid culture as Pdgfra+ cells.

Figure 6.1: Murine AT2s gating strategies. a,b, Flow cytometry gating strategy for murine AT2s
using MHCII as a positive marker (a) or without using MHCII as a positive marker (b). The right
column contour plots are the same as the final pseudocolor plots in the corresponding gating
strategies, and they are shown to highlight the final AT2 population defined from each strategy. c,
Comparison of the two populations of AT2s identified by the two gating strategies in terms of
MHCII expression (contour plot, left) or pro-SPC expression (histogram, right).

Figure 6.2: Human AT2s gating strategy. Flow cytometry gating strategy for human AT2s. The
right-most contour plot highlights in blue the final AT2 population defined by HT2-280+ staining.
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Flow cytometric detection of MHCII, peptide/MHCII complexes, and associated
machinery
To assess total surface MHCII expression in wild-type and knockout mice, cells
were stained with a pan I-A/I-E anti-MHCII antibody. Human MHCII was detected
using an anti-HLA-DR antibody. For detection of specific MHCII alleles in YAe
presentation assays, cells were surface stained with anti-I-Ab and anti-I-Ed antibodies.
Mouse invariant chain and H2M expression were detected by staining intracellularly
with anti-mouse CD74 and anti-H2Mab2 antibodies, respectively.

Two different

fluorophore-conjugated versions of the anti-H2Mab2 antibody were labeled in house,
with the Pacific Blue and Alexa Fluor 647 labeling kits (P30013 or A20186, Thermo
Fisher). Human invariant chain was detected using an anti-human CD74 antibody,
and HLA-DM was detected using an anti-HLA-DM antibody [227] provided by L.
Denzin (Rutgers). CLIP-loaded MHCII molecules were detected on the cell surface by
using an CLIP/I-Ab complex specific antibody [227] provided by L. Denzin (Rutgers).
To detect Ea52-68/I-Ab complexes, lung cells were surface stained with a biotinylated
Y-Ae antibody followed by APC-Streptavidin (405207, Biolegend).

Costimulatory molecule expression analysis
To generate bone marrow-derived dendritic cells (BMDCs), bone marrow cells
were grown in complete RPMI media supplemented with 20 ng/mL mouse
recombinant granulocyte-macrophage colony-stimulating factor (“GM-CSF”; 10822026, Shenandoah Biotechnology). Fresh media was added on days 3 and 6 after
plating, and the floating fraction of cells was harvested on day 7-10.
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Mice were infected intranasally with 60 FFU IAV PR8 diluted in 20 µL PBS
under isoflurane anesthesia. Lungs were harvested from mice 5 days after infection
or from naïve mice.
To evaluate the expression of costimulatory molecules, BMDCs, bulk
splenocytes, and lung cells were surface stained with anti-CD80, anti-CD86, and antiCD54 (ICAM1) antibodies.

DQ-ovalbumin assay
0.75-1.25x105 AT2s, DCs, and B cells were incubated with either 0 or 10 µg/mL
DQ-ovalbumin (D12053, Thermo Fisher) in complete RPMI media at either 37°C or
4°C for 2 hours. Cells were then washed 3x with PBS and stained with Live/Dead
Aqua; cells were maintained at 4°C during these steps. Fluorescence was then
immediately assessed by flow cytometry.

RNA isolation and quantitative PCR
Total RNA was extracted and purified using the Qiaqen RNeasy Plus Mini Kit
(74134, Qiagen), and cDNA was then prepared using the SuperScript III First-Strand
Synthesis System with random hexamers (18080051, Thermo Fisher). Quantitative
PCR was performed using the Power SYBR Green PCR Master Mix system (4367659,
Thermo Fisher) measured using a StepOnePlus Real Time PCR Machine (Applied
Biosystems). Expression was quantified relative to the housekeeping gene Hprt using
the DCT method. The following forward (F) and reverse (R) primer pairs were used.
H2-Aa F: CTGATTCTGGGGGTCCTCGC and R: CCTACGTGGTCGGCCTCAAT;
H2-Ab1

F:

GAGCAAGATGTTGAGCGGCA

and

R:
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GCCTCGAGGTCCTTTCTGACTC; H2-DMa F: GGCGGTGCTCGAAGCA and R:
TGTGCCGGAATGTGTGGTT; H2-DMb1 F: CTATCCAGCGGATGTGACCAT and R:
TGGGCTGAGCCGTCTTCT;

Hprt

F:

TCAGTCAACGGGGGACATAA

and

R:

GGGGCTGTACTGCTTAACCAG.

Bone marrow chimeras
Donor bone marrow was isolated from C57Bl6 MHCII-/- and CD45.1 B6 mice,
and T cells were depleted magnetically using Thy1.2 Dynabeads (11443D, Thermo
Fisher).

5x106 bone marrow cells were then injected intravenously into lethally

irradiated recipient C57Bl6 MHCII-/- and CD45.1 B6 mice 6 hours after irradiation was
completed (5.5 Gy x 2 doses, 3 hours apart). Mice were treated with Bactrim for 3
weeks following the transfer and were housed in autoclaved cages.
Full bone marrow chimera reconstitution was confirmed 6 weeks after transfer,
by flow cytometry analysis of peripheral blood cells stained with anti-CD45.1 and antiCD45.2 antibodies. MHCII expression on chimeric mouse lung cells was assessed 8
weeks post-transfer.

Detection of germline MHCII deletion
Consistent with prior reports [228, 229], our Ab1fl/fl mice experienced
spontaneous germline disruption of the I-Ab locus at a rate of ~5%, resulting in global
loss of MHCII from all cells. Therefore, in addition to standard genotyping all SPCDAb1
and Ab1fl/fl mice were screened at >5 weeks of age for germline deletion of MHCII, by
flow cytometric measurement of MHCII on peripheral blood immune cells isolated by
cheek bleed. Specifically, cells were stained for surface expression of CD45, CD19,
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and MHCII, and mice were excluded from further study if B cells (CD45+ CD19+) lacked
MHCII expression. All mice included in experiments discussed here had appropriately
intact MHCII expression by peripheral blood screening.

Tamoxifen administration
SPCDAb1, Ab1fl/fl, and SPCCre mice >5 weeks of age were oral gavaged daily
with 2 mg tamoxifen for 4 days, by delivering 100 µL of 20 mg/mL solution of tamoxifen
(T5648, Sigma) in a 9:1 corn oil:ethanol mixture. Mice were used in experiments ³5
days after the last dose of tamoxifen.

Histological analysis
To assess MHCII expression in SPCDAb1, Ab1fl/fl, and MHCII-/- mice by
immunofluorescence, the lung vasculature was first perfused with 5 mL 4%
paraformaldehyde in PBS (4% PFA) by injecting into the cardiac right ventricle. Lungs
were then inflated via intratracheal instillation of 0.9 mL 4% PFA. The trachea was
then tied with suture to keep the lungs inflated while they were excised en bloc and
then placed in an additional 30 mL 4% PFA, then incubated for 24 hours at 4°C. Tissue
was then processed, paraffin-embedded, sectioned, and stained with DAPI, and the
following antibodies: anti-mouse pro-SPC (AB3786, EMD Millipore), anti-mouse
MHCII (107601, Biolegend), and anti-mouse E-cadherin (ab76319, Abcam). Images
were acquired using an Axio Observer 7 widefield microscope with Axiocam 702
monochrome CMOS camera and Zen blue acquisition software (Zeiss). Composite
images were then generated in Fiji.
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To assess lung pathology at homeostasis in SPCDAb1 and Ab1fl/fl mice, the lungs
were inflated via intratracheal instillation of ~1 mL 10% neutral buffered formalin
(NBF), then placed in an additional ~30 mL 10% NBF and incubated for 24 hours at
RT. Tissue was then processed, paraffin-embedded, sectioned, and stained with
hematoxylin and eosin, and the resulting lung sections were evaluated for signs of
disease by a veterinary pathologist. Images were acquired using an Axio Observer 7
widefield microscope with Axiocam 503 color CCD camera and Zen blue acquisition
software (Zeiss).

T cell phenotyping analyses
For determination of T cell phenotype as well as activation status, cells were
surface stained for the following markers: CD44, CD62L, CD69, CD11a, PD1, and
LAG3. Cells were also stained intranuclearly for FoxP3 and Ki67.

Lung organoids
Alveolar organoids were cultured as described previously [115, 143], with the
following modifications. Briefly, 5x103 AT2s sorted from either SPCDAb1 and Ab1fl/fl mice
were cocultured with 5x104 Pdgfra+ lung fibroblasts sorted from WT C57Bl/6 mice.
Cells were suspended in 90µL of a 1:1 mixture of Matrigel:modified SAGM media (CC3118, Lonza). SAGM media is modified by adding 0.1 µg/mL cholera toxin (C8052,
Sigma) and the following SAGM BulletKit components: 10 µg/mL insulin, 5 µg/mL
transferrin, 25 ng/mL EGF, 30 µg/mL bovine pituitary extract, 0.01µM retinoic acid,
and 5% FBS. The 1:1 mixture containing cells was placed in a cell culture insert
(353095, Corning); after solidification of the matrix at 37°C, the insert was placed
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inside a well of 24-well plate containing modified SAGM media. For the first two days
of culture, 10 µM ROCK inhibitor Y27632 (Y0503, Sigma) was added to the media.
The media was changed every 48 hours, and after 21 days organoids were imaged
using an EVOS FL Auto. Organoid numbers were quantified in Fiji using the Cell
Counter plugin.

Virus infections for weight loss and mortality analysis
For influenza infection weight loss monitoring, mice were infected intranasally
with 3 FFU IAV PR8 diluted in 20 µL PBS under isoflurane anesthesia. For influenza
infection mortality experiments, mice were infected intranasally with 15 FFU IAV PR8
diluted in 20 µL PBS under isoflurane anesthesia. For both Sendai virus infection
weight loss monitoring and mortality analyses, mice were infected intranasally with
3.5-7x104 TCID50 SeV 52 diluted in 35 µL PBS under ketamine (70 mg/kg) + xylazine
(5 mg/kg) anesthesia. For all weight loss experiments, mice were weighed on the days
indicated. For all mortality studies, mice were monitored daily for death or moribund
state as an endpoint.

Lung virus titering
For influenza virus titering, mice were infected intranasally with 3 FFU IAV PR8
diluted in 35 µL PBS under ketamine (70 mg/kg) + xylazine (5 mg/kg) anesthesia. For
Sendai virus titering, mice were infected intranasally with 7x104 TCID50 SeV 52 diluted
in 35 µL PBS under ketamine (70 mg/kg) + xylazine (5 mg/kg) anesthesia. Mice were
sacrificed at the timepoints indicated for virus titers analysis.
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For influenza virus titers determination, MDCK cells were infected with serial
10-fold dilutions of lung homogenates in MEM containing 50µg/mL gentamicin, 5mM
HEPES, and 1µg/mLTPCK-treated trypsin (LS003750, Worthington Biochemical) in
quadruplicate per lung. After 4 days of incubation at 37°C, the presence of virus at
each dilution was determined by visual cytopathic effect, and lung virus titers were
determined using the Reed and Muench Calculation.
For Sendai virus titers determination, LLC-MK2 cells were infected with serial
10-fold dilutions of lung homogenates in DMEM containing 50µg/mL gentamicin,
0.35% BSA, 0.12% NaHCO3, and 2 µg/mL TPCK-treated trypsin in triplicate per lung.
After 3 days of incubation at 37°C, the presence of virus was determined by assessing
the capacity of 25µL of supernatant at each dilution to hemagglutinate 0.25% chicken
red blood cells (cRBCs) in a 100µL final volume after a 30” incubation at room
temperature. Lung virus titers were then determined using the Reed and Muench
Calculation.

Influenza LAG3+ T cell expansion analysis
Mice were infected intranasally with 3 FFU IAV PR8 diluted in 20 µL PBS under
isoflurane anesthesia. Mice were sacrificed 9 days after infection and lungs were
stained ex vivo for T cell surface markers and LAG3.

Hybridoma assay
NFAT-lacZ-inducible T cell hybridomas recognizing MHCII-restricted influenzaderived epitopes have been described previously [46, 178]. Hybridoma recognition of
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cognate peptide/MHCII complexes results in b-galactosidase production, which was
detected using a fluorometric β-galactosidase substrate 4-methyl-umbelliferyl-β-Dgalactopyranoside (“MUG”; M1633, Sigma).
1x104 APCs were treated with media only, 20 µg/mL peptide, or 1x106 FFU
influenza virus in complete RPMI media for 45” at 37°C, 6% CO2 in a 384 well plate;
for AT2 conditions, wells were pre-coated with a thin layer of 9:1 RPMI:Matrigel
(356231, Corning) mixture. After 45”, 2x104 hybridomas were directly added, and cells
were then cocultured for 14-18 hours at 37°C, 6% CO2. MUG substrate solution (33
µg/mL MUG in PBS containing 38.5 µM 2-mercaptoethanol, 9 mM MgCl2, and 1.25%
NP40) was then added to the co-culture at a ratio of 1:5 MUG solution:co-culture, then
incubated for 3 hours at 37°C, 6% CO2. Fluorescence (excitation: 365 nm, emission:
445nm) was detected on Tecan Infinite M200 Pro Plate Reader.

IFNg ELISpot assay
For isolation of influenza-infected APCs, WT and MHCII-/- mice were infected
intranasally with 1.2x106 FFU IAV PR8 diluted in 35 µL PBS under ketamine (70
mg/kg) + xylazine (5 mg/kg) anesthesia. Lungs were harvested from mice 4 days after
infection or from naïve mice. APCs were isolated via cell sorting, as above.
For isolation of influenza-experienced effector T cells, WT mice were infected
intranasally with 3 FFU IAV PR8 diluted in 35 µL PBS under ketamine (70 mg/kg) +
xylazine (5 mg/kg) anesthesia. Spleens were harvested from mice 10 days after
infection.

CD4+ and CD8+ T cells were isolated from bulk splenocytes using
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Dynabeads Untouched Kits for mouse CD4 cells and CD8 cells, respectively, per the
manufacturer’s protocol (11415D and 11417D, Thermo Fisher).
96-well MultiScreenHTS IP 0.45 µm filter plates (MSIPS4W10, Millipore-Sigma)
were coated with mouse IFNg capture antibody (551881, BD) and incubated at 4°C for
20 hours prior to the assay. Plates were blocked with complete RPMI media for >1
hour at 37°C, after which 5x104 APCs and 1x105 T cells were co-cultured for 14-18
hours in the presence of 2µg/mL anti-CD28 (40-0281-M001, Tonbo Biosciences). T
cell IFNg production was detected via biotinylated IFNg detection antibody (551881,
BD), followed by HRP-Streptavidin (557630, BD) and chromogenic 3-Amino-9ethylcarbazole (AEC) substrate (551951). IFNg spots were imaged and counted using
a CTL ImmunoSpot S6 Universal Analyzer.

Detection of influenza-infected cells
For quantification of influenza virus infection in hybridoma and ELISpot assays,
at assay endpoint cells were stained for surface hemagglutinin (HA) protein
expression or intracellular nucleoprotein (NP) protein expression.

Two different

fluorophore-conjugated versions of the anti-HA antibody were labeled in house, with
the Alexa Fluor 488 and Alexa Fluor 647 labeling kits (A20181 or A20186, Thermo
Fisher).

IFNg treatment of mice
Mice were injected intravenously under isoflurane anesthesia once daily with
1x105 U recombinant mouse IFNg (575306, Biolegend) in 150 µL PBS, or PBS only,
for 3 days in a row.
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Inhaled Ova allergy model
Mice were injected intraperitoneally with 10µg ova (A5503, Sigma) and 2.25mg
Alum (77161, Thermo Fisher) in 200µL on days 0 and 14. 10µg ova protein in 20µL
PBS was then administered to mice intranasally under isoflurane anesthesia once
daily on days 28, 29, and 30. BAL cells and lung T cells were harvested on day 31, as
described above.

Intracellular cytokine staining
For intracellular cytokine staining, lung cells from ova-immunized mice were
incubated in R10 media containing 2µg/mL anti-CD28, 50 ng/mL phorbol 12-myristate
13-acetate (PMA), 1µg/mL ionomycin, and 1X brefeldin-A (420601; Biolegend) for 5
hours at 37°C. Cells were then surface stained with anti-mouse CD8, and
intracellularly with antibodies against mouse CD3, CD4, IL5, IL13, IL17, and IFNg.

Analysis of publicly available RNA-sequencing data
For analysis of H2Mb1 and H2Mb2 expression by B cell, dendritic cell, and
macrophage subsets, bulk RNA-sequencing data was obtained using the
Immunological Genome Project [153] Gene Skyline RNA-seq Data Browser, available
at (http://rstats.immgen.org/Skyline/skyline.html).
For analysis of AT2 cells by bulk RNA-sequencing and single cell RNAsequencing, data were obtained from the LungMAP consortium, which is funded by
1U01HL122638. The bulk RNA-sequencing dataset was contributed by Jeffrey A.
Whitsett

(CCHMC)

and

Yan

Xu

(CCHMC),

and

is

available

at
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(https://www.lungmap.net/breath-omics-experiment-page/?experimentTypeId=LMXT000
0000018&experimentId=LMEX0000001223&analysisId=LMAN0000000225&view=allEnti
ties). The single cell RNA-sequencing dataset was contributed by Jeffrey A. Whitsett

(CCHMC), Bruce Aronow (CCHMC), and S. Stephen Potter (CCHMC), and is
available at:
(https://www.lungmap.net/breath-omics-experiment-page/?experimentTypeId=LMXT
0000000016&experimentId=LMEX0000001602&analysisId=LMAN0000000107&vie
w=allEntities).

Statistical analysis
All statistical analyses were performed using Prism 8 software (GraphPad).
The statistical tests used are indicated in the figure legend corresponding to each
specific experiment. Unpaired two-tailed Student’s t-test was used to compare means
between two groups if they had similar variances by F-test, and if they passed all four
of the following normality of residuals tests: Anderson-Darling, D’Agostino-Pearson
omnibus, Shapiro-Wilk, and Kolmogorov-Smirnov. If variances were significantly
different, unpaired two-tailed Welch’s t-test was used, and if the samples failed at least
one normality test then two-tailed Mann-Whitney test was used. For weight loss
analysis, a mixed model, which uses a compound symmetry covariance matrix and is
fit using Restricted Maximum Likelihood (REML), with Geisser-Greenhouse correction
was used, followed by post-hoc multiple comparisons with Sidak’s correction; this was
used instead of repeated-measures ANOVA, as it can handle missing values. For
mortality analysis, the Log-rank (Mantel-cox) test was used to compare survival
curves. Two-way ANOVA followed by post-hoc multiple comparisons with Tukey’s or
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Sidak’s correction was used to compare means between groups with 2 contributing
independent variables; Tukey’s correction was used when all possible means were
compared, and Sidak’s correction was used when means were compared across one
factor only. Three-way ANOVA followed by post-hoc multiple comparisons with
Sidak’s correction was used to compare means between groups with 3 contributing
independent variables.
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Flow cytometry antibodies used
Target
Clone or Catalog #
Source
mouse CD45
30-F11
Biolegend
mouse CD31
390
Biolegend
mouse EpCAM (CD326)
G8.8
Biolegend
mouse I-A/I-E (MHCII)
M5/114.15.2
Biolegend
mouse proSP-C
AB3786
Sigma Aldrich
human HT2-280
TB-27AHT2-280
Terrace Biotech
mouse IgM
II/41
Thermo Fisher
mouse CD11c
N418
Biolegend
mouse CD103
2E7
Biolegend
mouse CD11b
M1/70
BD
mouse CD64
X54-5/7.1
Biolegend
mouse CD3
145-2C11 or 17A2
BD or Biolegend
mouse CD8
53-6.7
BD
mouse CD19
6D5
Biolegend
mouse B220
RA3-6B2
Biolegend
mouse CD4
RM4-5 or GK1.5
Biolegend
mouse NK1.1
PK136
Thermo Fisher
GL3
Biolegend
mouse TCRd
mouse Ly6G
1A8
BD
mouse SiglecF
E50-2440
BD
mouse Podoplanin
8.1.1
Thermo Fisher or Biolegend
mouse Sca-1
D7
Thermo Fisher
mouse CD34
MEC14.7
Biolegend
APA5
Thermo Fisher
mouse Pdgfra (CD140a)
human HLA-DR
G46-6
BD
mouse I-Ab
AF-120.1
Thermo Fisher
mouse I-Ed
14-4-4S
Biolegend
mouse invariant chain (CD74)
In-1
BD
2E5A
BD
mouse H2Mab2
human invariant chain (CD74)
Pin.1
Biolegend
human HLA-DM
Map.DM1
L. Denzin
mouse CLIP/I-Ab
15G4
L. Denzin
YAe
Thermo Fisher
mouse Ea52-68/I-Ab
mouse CD80
16-10A1
BD
mouse CD86
GL1
BD
mouse ICAM-1 (CD54)
YN1/1.7.4
Biolegend
mouse CD45.1
A20
Biolegend
mouse CD45.2
104
Biolegend
influenza hemagglutinin (HA)
IC5-4F8
BEI
influenza nucleoprotein (NP)
D67J
Thermo Fisher
mouse CD44
IM7
Biolegend
mouse CD62L
MEL-14
Biolegend
mouse CD69
H1.2F3
Biolegend
mouse CD11a
M17/4
Biolegend
mouse PD1
RMP1-30
Biolegend
mouse LAG3
C9B7W
Biolegend
mouse Foxp3
FJK-16s
Thermo Fisher
mouse Ki67
16A8
Biolegend
mouse IL5
TRFK5
Biolegend
mouse IL13
eBio13A
Thermo Fisher
mouse IL17
TC11-18H10.1
Biolegend
XMG1.2
Biolegend
mouse IFNg
Table 6.1: Flow cytometry antibodies used for all studies.
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